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Sprouty (Spry) proteins modulate Receptor Tyrosine Kinase (RTK) signaling to 
regulate key biologic pathways. Spry was first identified by Hacohen et al., who 
reported that mutations in Drosophila Spry resulted in hyper-branching in Fibroblast 
growth factor (FGF) mediated lung tubular morphogenesis (Hacohen et al., 1998). 
The role of Spry in the lung branching programme was subsequently observed in mice 
(Metzger et al., 2008; Tang et al., 2011). Spry proteins also regulate growth factor 
mediated processes including outgrowths in neuronal cells and neuritogenesis (Gross 
et al., 2007; Hausott et al., 2009; Wong et al., 2002). In breast, liver and prostate 
cancers, Spry expression is downregulated (Fong et al., 2006; Lo et al., 2004; Patel et 
al., 2013) and thus Spry is suggested to be a tumor suppressor. However, Spry2 
promoted epithelial-mesenchymal transition and metastasis in colorectal cancers 
(Barbáchano et al., 2010; Holgren et al., 2010) and Spry2 protein levels also 
correlated with poor colon carcinoma patient survival (Ordóñez-Morán et al., 2013), 
suggesting that Spry2 may have oncogenic functions. The discrepancy of the role of 
Spry2 in cancers may be due to the differential functions of Spry2 in signaling 
pathways; Spry2 inhibits FGF-RAS-ERK signaling (Casci et al., 1999; Hacohen et al., 
1998; Lao et al., 2006; Yusoff et al., 2002), while potentiating the EGF-ERK axis 
(Rubin et al., 2003; Wong et al., 2002).   
The involvement of Spry proteins in a myriad of biological and pathological 
processes demonstrates the importance of understanding how this family of proteins is 
regulated. Two events are necessary for Spry2 to inhibit FGF-RAS-ERK signaling. 
First, Spry2 protein translocates to the plasma membrane upon growth factor 
stimulation (Casci et al., 1999; Lim et al., 2000). Second, Spry2 binds to Grb2 during 
signaling (Hanafusa et al., 2002; Lao et al., 2006), which results in Spry2 competing 
with SOS1 for Grb2, thus disrupting the signaling pathway upstream of RAS and 
RAF (Lao et al., 2006). In order for the Spry2-Grb2 interaction to occur, a cryptic C-
terminal PxxPxR motif on Spry2 is revealed upon FGFR1 activation. The PxxPxR 
motif is then available for binding to the SH3 domain of Grb2 (Guy et al., 2009; Lao 
et al., 2007). The changes in Spry2 tertiary structure that enable binding to Grb2 is 
thought to be governed by serine/threonine (S/T) phosphorylation of the conserved 
serine/threonine rich (STR) region of Spry2 (Guy et al., 2009).  
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Consistent with the model of S/T phosphorylation influencing Spry2 activation, 
two residues in the STR region of Spry2, S112 and S115, are found dephosphorylated 
in the presence of FGFR1 signaling (Lao et al., 2007). The residues S112 and S115 
match perfectly the consensus phosphorylation motif (pS/T-X-X-S/T) of Casein 
Kinase 1 (CK1). Moreover, Lao et al. also identified certain serines within the STR 
region that are responsible for Spry2 band electrophoretic mobility shifts, indicative 
of S/T phosphorylation changes (Lao et al., 2007). Among these residues, S112, 
S115, S118, S121, S124, S127, S130 constitute a series of CK1 phospho-motifs, 
raising the question if CK1 regulates Spry2. 
CK1 is a family of major cellular serine/threonine protein kinases that is encoded 
by six genes (α, γ1, γ2, γ3, δ and ε). CK1s regulate several signaling pathways 
including the Wnt/β-catenin pathway, Hedgehog signaling, circadian rhythms and the 
p53 tumor suppressor pathways (reviewed in (Cheong and Virshup, 2011)). CK1 is 
not yet implicated in FGF-ERK signaling. 
In this thesis I investigate whether CK1 activates Spry2 inhibition of FGF-ERK 
signaling, through mediation of Spry2-Grb2 interaction. In addition, I explore the role 
of CK1 regulating the capacity of Spry2 in FGF/NGF mediated neurite outgrowths of 
PC12 neuronal cells, and discuss the relevance of the CK1-Spry2 interaction in 
human cancers. I present unpublished work looking at CK1 and Spry2 in Xenopus 
developmental biology, as well as CK1-Spry2 biochemistry. Finally, I discuss the 
future directions and technical considerations that arise from my work. 
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unique C-terminal Grb2 binding domain. 
 
Figure 1.7  Sequence conservation and domain organization of human Spry family 
(alignment generated by Daniel Yim for (Guy et al., 2009)). In red 
highlight: the 50-60 region that binds c-Cbl. Green highlight: the 
serine/threonine rich region and in blue highlight: the cysteine rich 




Figure 1.8  Chemical structures of (L to R) PF670462, PF4800567 (adapted from 
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Figure 3.2  Flag-tagged SPRY2 was tested for interaction with endogenous CK1ε. 
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hours. Cells were lysed 16-18 hours after transfection of the indicated 
constructs, followed by immunoprecipitation of the indicated proteins. 
(* indicates IgG heavy chain. Henceforth WCL, whole cell lysate and 
numbers at the left side of blot scans indicate molecular weight 
reference markers in kilo Daltons.) 
 
Figure 3.3  Endogenous CK1δ immunoprecipitates (IPs) were tested for Flag-
tagged SPRY2. The various constructs were expressed in HEK 293 
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Figure 3.4  Endogenous CK1α was analyzed for interaction with Flag-tagged 
SPRY2. The various constructs were expressed in HEK 293 cells for 
16-18 hours. Cells were lysed 16-18 hours after transfection of the 
indicated constructs, followed by immunoprecipitation of the indicated 
proteins. 
 
Figure 3.5  Flag-tagged SPRY2 was overexpressed in HEK 293 cells and Flag IPs 
were tested for HA-tagged CK1s. 
 
Figure 3.6  Quantitation of CK1ε binding to SPRY2, with and without FGFR1 in 
HEK293 cells, from three independent experiments. Band intensities 
were quantitated using ImageJ, and normalized to Flag-SPRY2 input 
in the whole cell lysates and total CK1 in the immunoprecipitates. p = 
0.039. 
 
Figure 3.7  Quantitation of CK1δ binding to SPRY2, with and without FGFR1 in 
HEK293 cells, from three independent experiments. Band intensities 
were quantitated using ImageJ, and normalized to Flag-SPRY2 input 
in the whole cell lysates and total CK1 in the immunoprecipitates. 
 
Figure 3.8  Quantitation of CK1α binding to SPRY2, with and without FGFR1 in 
HEK293 cells, from three independent experiments. Band intensities 
were quantitated using ImageJ, and normalized to Flag-SPRY2 input 
in the whole cell lysates and total CK1 in the immunoprecipitates. 
 
Figure 3.9  Flag-tagged SPRY2 was expressed in HEK 293 cells. Cells were then 
treated with DMSO or PF670, and subsequently with Calyculin A to 
stimulate SPRY2 phosphorylation. Endogenous CK1ε was 
immunoprecipitated and analyzed for interaction with Flag-tagged 
SPRY2. 
 
Figure 3.10  Kinase dead D128N CK1ε was analyzed for binding to SPRY2. 
Flagged tagged SPRY2 and HA-tagged wildtype CK1ε or kinase dead 
CK1ε were co-expressed in HEK 293 cells. 
 
Figure 3.11 Kinase dead K38R CK1δ was tested for binding to SPRY2. Flagged 
tagged SPRY2 and Myc-tagged wildtype CK1δ or kinase dead CK1δ 
were co-expressed in HEK 293 cells. 
 
Figure 3.12  Schematic diagram of SPRY2 truncation mutants tested for interaction 
with HA-tagged CK1ε. (+ indicates constructs that bind to HA-CK1ε.) 
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Figure 3.13  Schematic diagram of SPRY2 truncation mutants tested for interaction 
with endogenous CK1ε. (+ indicates constructs that bind to 
endogenous CK1ε.). 
 
Figure 3.14  SPRY2 truncation mutants binding to HA-tagged CK1ε. Flag-tagged 
wildtype SPRY2 or truncated SPRY2 mutants were co-expressed with 
HA-tagged CK1ε in HEK 293 cells for 16-18 hrs, before Flag-tagged 
SPRY2 and mutants were immunoprecipitated. 
 
Figure 3.15  SPRY2 truncation mutants binding to endogenous CK1ε. Flag-tagged 
wildtype SPRY2 or truncated SPRY2 mutants were expressed in HEK 
293 cells for 16-18 hrs, before immunoprecipitation of endogenous 
CK1ε. 
 
Figure 3.16  A SPRY2 construct lacking the first CK1ε binding site (SPRY2Δ211-
230) transiently expressed in HEK293 cells was tested for binding to 
endogenous CK1ε by immunoprecipitation, SDS-PAGE, and 
immunoblotting using the indicated antibodies. 
 
Figure 3.17  SPRY2 constructs lacking the second CK1ε binding region 
(SPRY2Δ179-192), and both binding regions (SPRY2Δ179-192Δ211-
230, or SPRY2ΔΔ) were generated. Endogenous CK1ε 
immunoprecipitates were tested for Flag-tagged SPRY2 and mutant in 
HEK 293 cells. 
 
Figure 3.18  Endogenous CK1δ was analyzed for interaction with Flag-tagged 
SPRY2 with and without FGFR1 in HEK 293 cells. 
 
Figure 3.19  Flag-tagged SPRY2ΔΔ was tested for membrane translocation in COS-
1 cells, stimulated by bFGF or NGF. Cortactin is used as a membrane 
marker. 
 
Figure 3.20  The interaction of endogenous c-CBL and ectopically expressed Flag-
tagged wildtype and mutant SPRY2, as indicated, were analyzed by 
immunoprecipitation and immunoblotting. FGFR1 and the CK1 
inhibitor PF670 were added where indicated. Disheveled 2 (DVL-2) 
band shift was used as a readout for PF670 activity. Flag-SPRY2Δ50-
60 was reported to be a non-binder of c-CBL and was used as a 




Figure 3.21  Time course of ERK activation after bFGF stimulation in the absence 
or presence of ectopic SPRY2, analyzed by SDS-PAGE and 
immunoblotting. HEK 293 cells were transiently transfected with 
empty vector or Flag-tagged SPRY2. 16-18 hrs after transfection, cells 
were serum starved for 2 hrs and subsequently stimulated with growth 
factor for the indicated durations. (EV, empty vector.) 
 
Figure 3.22  HEK293 cells were transfected with 5 ng Flag-tagged ERK2, and 10 
ng Flag-SPRY2 expression plasmids or empty vector as indicated. 
CK1 inhibition with 1 µM PF670 for 1 hr, before serum starvation of 2 
hrs and 6 min growth factor stimulation, abrogates the effect of SPRY2 
in inhibiting bFGF-ERK signaling at 7 minutes post-stimulation. 
Asterisks indicate T-tests for significance (*, p = 0.035, **, p = 0.01, 
n.s., not significant). Quantitation obtained from three independent 
experiments. 
 
Figure 3.23  PF670 prevents SPRY2 inhibition of bFGF-ERK signaling. HEK 293 
cells were transiently transfected with Flag-tagged SPRY2. 16-18 hrs 
after transfection, cells were serum starved for 2 hrs and subsequently 
stimulated with growth factor for the indicated durations. 
 
Figure 3.24  D4476 abrogates SPRY2 inhibition of bFGF-ERK signaling at 7 
minutes post-stimulation. Asterisks indicate T-tests for significance (*, 
p = 0.032, **, p = 0.033). Quantitation obtained from three 
independent experiments. 
 
Figure 3.25  Flag-tagged SPRY2ΔΔ is less effective than wild-type Flag-SPRY2 in 
suppression of bFGF-stimulated ERK signaling. 
 
Figure 3.26  HEK 293 cells expressing FGFR1 and Flag-tagged SPRY2 were 
treated with DMS or PF670 as indicated. Flag-IPs were tested for 
endogenous GRB2. 
 
Figure 3.27  HEK 293 cells expressing FGFR1 and Flag-tagged SPRY2 were 
treated with DMSO or D4476 as indicated. Flag-IPs were tested for 
endogenous GRB2. 
 
Figure 3.28  Flag-tagged SPRY2ΔΔ was tested for interaction with endogenous 
GRB2 in HEK 293 cells. 
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Figure 3.29  Flag-tagged SPRY2ΔΔ IPs were tested for interaction with HA-tagged 
DYRK1A and Myc-tagged TESK1. HEK 293 cells were used in (B) 
and (C). (* indicates non-specific band.) 
 
Figure 3.30  MetaMorph quantitation of bFGF induced neurite outgrowth with 
representative images of cells. Cells were transfected with Flag-tagged 
wildtype or SPRY2ΔΔ expression vectors. PF670 was used at 1 µM, 
and D4476 was used at 10 µM in all the experiments. 
 
Figure 3.31  Mean number of neurite processes in PC12 cells transfected with 
various SPRY2 constructs under the indicated conditions. Error bars 
indicate the 95% confidence intervals of the mean. 
 
Figure 3.32  MetaMorph quantitation of NGF induced neurite outgrowth with 
representative images of cells. Cells were transfected with wildtype 
SPRY2 or Flag-tagged SPRY2ΔΔ. 
 
Figure 3.33  Mean number of neurite processes in PC12 cells transfected with 
various SPRY2 constructs, subjected to the indicated conditions. Error 
bars indicate 95% confidence intervals. 
 
Figure 3.34  MetaMorph quantitation of neurite outgrowth of PC12 cells in the 
presence of CK1 inhibitors PF670 and D4476. 
 
Figure 3.35  Mean number of neurite outgrowths in PC12 cells with and without 
CK1 inhibitors. Error bars indicate the 95% confidence intervals of the 
mean. 
 
Figure 3.36  Representative images of PC12 cells. Cells were transfected with 
either empty vector plasmids or Flag-SPRY2. Subsequently, cells were 
pre-treated with DMSO, 1 µM PF670 or 10 µM D4476 1 hour prior to 
bFGF or NGF stimulation for 3 days. 
 
Figure 3.37  Representative images of PC12 cells. Cells were transfected with 
either empty vector plasmids or Flag-SPRY2. Subsequently, cells were 
pre-treated with DMSO, 1 µM PF670 or 10 µM D4476 1 hour prior to 
bFGF or NGF stimulation for 3 days. 
 
Figure 3.38  Representative images of PC12 cells. Cells were transfected with 
either empty vector plasmids, Flag-SPRY2 or Flag-SPRY2. 
Subsequently, cells were stimulated with bFGF or NGF for 3 days. 
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Figure 3.39  CSNK1E negatively correlates with FGF1 transcripts in human gastric 
cancers. Log2 values of the indicated gene expression are plotted 
against FGF expression quartiles (Q1 being the lowest value, and Q4 
the highest). P-values of difference between quartiles are indicated. (* 
indicates significance; n.s., not significant.) 
 
Figure 3.40  CSNK1E negatively correlates with FGF7 transcripts in human gastric 
cancers. Log2 values of the indicated gene expression are plotted 
against FGF expression quartiles (Q1 being the lowest value, and Q4 
the highest). P-values of difference between quartiles are indicated. (* 
indicates significance; n.s., not significant.) 
 
Figure 3.41  CSNK1E and SPRY2 boxplots against FGF4 quartiles. 
 
Figure 3.42  A second CSNK1E probe was tested for correlation with FGF1, 4 and 7 
gene expression. CSNK1E boxplots against (from top to bottom) 
FGF1, FGF4 and FGF7 quartiles. 
 
Figure 3.43  CSNK1A1 boxplots against (from top to bottom) FGF1, FGF4 and 
FGF7 quartiles. 
 
Figure 3.44  CSNK1D boxplots against (from top to bottom) FGF1, FGF4 and 
FGF7 quartiles. 
 
Figure 3.45  Model of SPRY2 activation in the FGF-ERK pathway. Resting state 
SPRY2 adopts a conformation with its PxxPxR domain inaccessible 
for GRB2 binding. During FGF signaling, phosphorylation changes on 
SPRY2 due to both S/T kinases and phosphatases, such as CK1 and 
PP2A, facilitate the unmasking of the GRB2 interaction motif. This 
leads to SPRY2 sequestration of GRB2, and inhibition of FGF 
signaling to ERK. 
 
Figure 3.46  Sequence conservation in the human SPRY family. Multiple sequence 
alignment was generated with ClustalX. CK1ε binding sites on SPRY2 
and the corresponding sequences in the other family members are 
indicated with yellow highlights. Conserved residues are indicated in 
bold font. Green highlights the STR domain on SPRY2 and the 
corresponding sequences in the other family members. 
 
Figure 3.47  Flagged tagged SPRY1 was tested for interaction with HA-tagged 
CK1α, δ and ε in HEK 293 cells. 
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Figure 3.48  Flagged tagged SPRY4 was tested for interaction with HA-tagged 
CK1α, δ and ε in HEK 293 cells. 
 
Figure 4.1 Site directed mutagenesis of Spry2 aa 211-230. Point mutants are 
tested for interaction with endogenous CK1ε. 
 
Figure 4.2  Site directed mutagenesis of Spry2 aa 179-192 in the context of 
Spry2Δ211-230. Point mutants are tested for interaction with 
endogenous CK1ε. 
 
Figure 4.3  Morpholino knockdown of Spry2 and CK1 isoforms in Xenopus 
Laevis. 
 
Figure 4.4  Inhibition of CK1 kinase activity potentiates FGF-ERK signaling in 
Xenopus Laevis animal caps. 
 
Figure 4.5  GSK3β requires CK1ε for binding to Spry2. HEK 293 cells were 
transfected with FGFR1, HA-tagged CK1ε, HA-tagged GSK3β and 
Flag-tagged Spry2 as indicated. Plasmids were expressed for 16-18 hrs 
before cell lysis and immunoprecipitation of Flag-tagged Spry2 to look 
for GSK3β and CK1ε. 
 
Figure 4.6  HEK 293 cells were transfected with indicated siRNA for 4-5 hrs and 
left to incubate for 2 days. Empty vector or Flag-tagged Spry2 were 
then transfected into the cells as indicated and left to express for 16-18 
hrs. Cells were then serum starved for 2 hrs before stimulation with 5 
ng/ml bFGF. Cells were then lysed and protein lysates analyzed for the 
indicated proteins. 
 
Figure 4.7  HEK 293 cells were transfected with indicated siRNA for 4-5 hrs and 
left to incubate for 2 days. Empty vector or Flag-tagged Spry2 were 
then transfected into the cells as indicated and left to express for 16-18 
hrs. Cells were then serum starved for 2 hrs before stimulation with 5 









Figure 4.8  HEK 293 cells were transfected with indicated siRNA for 4-5 hrs and 
left to incubate for 2 days. Empty vector or Flag-tagged Spry2 were 
then transfected into the cells as indicated and left to express for 16-18 
hrs. Cells were then serum starved for 2 hrs before stimulation with 5 
ng/ml bFGF. Cells were then lysed and protein lysates analyzed for the 
indicated proteins. 
 
Figure 4.9  HEK 293 cells were transfected with indicated siRNA (*100 nM total 
per sample) for 4-5 hrs and left to incubate for 2 days. Flag-tagged 
Spry2, FGFR1 and ERK2 were then transfected into the cells as 
indicated and left to express for 16-18 hrs. Cells were then lysed, Flag-
tagged Spry2 immunoprecipitated and tested for Grb2. 
 
Figure 4.10  Empty vector or Flag-tagged Spry2 were transfected into HEK 293 
cells as indicated and left to express for 16-18 hrs. Cells were treated 
with PF670 and D4476 at the indicated concentration for 2 hrs. Cells 
were then lysed and endogenous CK1ε immunoprecipitated and tested 
for Flag-tagged Spry2. Dvl2 bandshift serves as a functionality of CK1 
inhibitors. Protein bands were quantified using ImageJ. 
 
Figure 5.1  Spry2 protein expression levels in a panel of cell lines.  Cell lysates 
were lysed in 10% SDS buffer and quantitated. PP2A-A protein was 
used as an equal protein loading marker, and overexpressed Flag-
tagged Spry2 in HEK 293 cells was used as a positive control. 
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Chapter 1. INTRODUCTION 
1.1 Cell signaling – Receptor Tyrosine Kinase Signaling 
In the eukaryotic cell, proteins interact and communicate with each other within 
distinct frameworks – cell signaling or signal transduction pathways. Functioning 
through these pathways, they transduce extracellular cues into changes in gene 
expression, cell fate and a myriad of physiological processes (e.g. proliferation and 
differentiation, migration, survival, metabolism, etc.). 
Regulatory mechanisms exist within these frameworks to ensure specificity in cell 
signaling and desired biological outcomes. Conversely with aberrant signaling, 
unbridled cell proliferation and migration may lead to the development of diseases 
such as cancers (reviewed in (Casaletto and McClatchey, 2012; Lemmon and 
Schlessinger, 2010)). Understanding the biochemical malfunctioning of pathway 
regulators in disease is thus important for the development of therapeutic strategies. 
An example of such a pathway modulator implicated in disease is the Sprouty (Spry) 
family of proteins ((Barbáchano et al., 2010; Ordóñez-Morán et al., 2013; Patel et al., 
2013) and reviewed in (Edwin et al., 2009b)), which regulate Receptor Tyrosine 
Kinase (RTK) signaling. Spry will be discussed in the following sections. 
Currently, 58 human RTKs classified under 20 subfamilies have been 
characterized. Each RTK has its distinct extracellular structural domains that 
recognize extracellular ligands such as Fibroblast Growth Factor (FGF), Epidermal 
Growth Factor (EGF) and Nerve Growth Factor (NGF). Upon ligand binding, several 
mechanisms of receptor activation ranging from self-oligomerization to ligand-
induced dimerization have been proposed to facilitate downstream signaling 
(reviewed in (Lemmon and Schlessinger, 2010)). In general, RTKs convert these 
extracellular cues into phosphorylation signals. These phosphorylation events occur 
on tyrosine, serine and threonine residues of pathway effectors. Hence, using 
phosphorylation as signaling “currency”, the RTKs transduce signals through 
signaling pathways to bring about changes in cell physiological processes. These 
processes in turn play essential roles in biological outcomes such as development and 
growth, oncogenesis, angiogenesis and synaptic plasticity. 
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RTKs signal through multiple pathways including the Rat Sarcoma–Mitogen 
Activated Protein Kinase (RAS-MAPK), Phosphoinositide 3-kinase–Protein Kinase B 
(PI3K-PKB), Phospholipase Cγ–Protein Kinase C (PLCγ-PKC) and Janus Kinase-
Signal Transducer and Activator of Transcription (JAK-STAT) cascades (Figure 1.1 
and reviewed in (Casaletto and McClatchey, 2012)). Adding to the diversity in 
signaling, ‘nodes’ such as RAS enable crosstalk between pathways, effectively 
forming a network from diverse linear cascades. Besides the MAPK, RAS activates at 
least two other effectors – PI3K and Ras Related Guanine nucleotide Exchange Factor 
(RalGEF). Although these three RAS activated pathways are best characterized, they 
do not represent the full complement of RAS effectors pathways as other less well 
understood candidate RAS effectors have been identified (reviewed in (Pylayeva-
Gupta et al., 2011)).  
 
Figure 1.1 A highly simplified schematic of signaling pathways activated by RTKs 
(adapted and modified from (Casaletto and McClatchey, 2012)). RTKs activate 
multiple downstream signaling pathways including the RAS-MAPK, RAS-RalGEF, 
PI3K, JAK/STAT, PLCγ and JNK pathways. 
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The MAPK effector pathway of RAS is essentially a tier of three serine/threonine 
(S/T) kinases: MAPKs that are phosphorylated and activated by MAPK-kinases 
(MAPKKs), which are regulated by MAPK-kinase-kinases (MAPKKKs). Taking into 
consideration that approximately 70 genes encode for about 200 MAPK cascade 
components, of which 12 MAPK, 7 MAPKKs and 7 MAPKKKs have been identified 
(listed in www.mapkinases.eu/mapk-resource), a multitude of possible MAPK 
modules can theoretically exist. Currently, at least four main arms of MAPK signaling 
cascades have been characterized, categorized according to the MAPK they activate 
(Figure 1.2). The Extracellular signal Regulated Kinase 1 and 2 (ERK1/2), ERK5, 
p38α-δ and cJun N-terminal Kinase (JNK) MAPK modules are ubiquitous in 
eukaryotic cells (reviewed in (Keshet and Seger, 2010)). These MAPK modules 
transduce a variety of signals ranging from stress, inflammatory cytokines, in addition 
to growth factors, into signals leading to cell growth, differentiation, tissue 
development, inflammatory responses, cell death and other physiological outcomes 
(reviewed in (Keshet and Seger, 2010; Wagner and Nebreda, 2009)). 
 
Figure 1.2 The main arms of MAPK signaling cascade (adapted from (Jeffrey et al., 
2007) and www.cellsignal.com/pathways/map-kinase.jsp). The MAPK arms are 
named after the MAPKs activated, i.e. ERK1/2, ERK5, p38 and JNK. 
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The RTK-MAPK cascade relevant to work presented in this thesis is the FGF-
ERK pathway, which is triggered when the extracellular signal FGF docks to the RTK 
FGF receptor (FGFR) resulting in receptor dimerization. This is coupled with auto-
phosphorylation of tyrosine residues on the intracellular domains of these receptors. 
FGFR recruits adaptor proteins like Fibroblast growth factor substrate 2 (FRS2). 
FRS2 itself is tyrosine phosphorylated and the phosphorylated tyrosines serve as 
docking sites for Src homology 2 (SH2) domains found in downstream signaling 
molecules like Growth factor receptor-bound protein 2 (Grb2). The Src homology 3 
(SH3) domain of Grb2 then recognizes proline rich sequences on the RAS-guanine 
exchange factor Son of sevenless (SOS). Grb2 activated SOS then facilitates the 
binding of Guanosine triphosphate (GTP) to the RAS-GTPase in exchange for 
Guanosine diphosphate (GDP). Activated RAS subsequently activates the RAF-




1.2 The RTK-RAS-ERK pathway in disease 
The RTK pathways govern key physiological processes like cell proliferation and 
migration, and its components are frequently implicated in disease. Overexpression 
and activating mutations of RTKs (e.g. EGF Receptor (EGFR) and Human Epidermal 
Growth Factor Receptor 2 (HER2)) are often associated with cancers. In fact, 
inhibitors against EGFR and HER2 are currently in the clinic for cancer therapy 
(reviewed in (Hynes and MacDonald, 2009)). Activating mutations of FGF receptors 
(FGFRs) and its gene amplifications are found in cancers. 10% of estrogen receptor 
(ER) positive breast cancers display amplification of FGFR1, while FGFR2 is 
upregulated in 10% of gastric cancers. Activating mutations in FGFR3 are also found 
in 50% of bladder cancers (reviewed in (Turner and Grose, 2010)). As FGF-FGFR 
signaling governs processes like angiogenesis, differentiation, proliferation and 
survival, deregulated FGF signaling is frequently found in both developmental 
syndromes and cancers. Gastric and colorectal cancers share the same S297PFGFR2 
mutations found in craniosynostosis syndromes such as the Apert, Pfeiffer and 
Crouzon syndromes (Jang et al., 2001), and K560EFGFR3 mutations in testicular 
tumors are also found in skeletal disorders such as Thanatophoric dysplasia (Goriely 
et al., 2009). FGFR2 and FGFR3 mutations are mutually exclusive with KRAS and 
HRAS mutations respectively (Byron et al., 2008; Jebar et al., 2005), suggesting that 
mutations in either are sufficient to trigger oncogenic RTK-RAS signaling. 
KRAS mutations were detected in 22% of all tumors in the Catalog of Somatic 
Mutations in Cancer (COSMIC) (COSMIC: www.sanger.ac.uk/genetics/CGP/cosmic 
and reviewed in (Prior et al., 2012)). These mutations (frequently at codon G12) 
render RAS GTPase deficient and thus constitutively active. RAF, which lies 
downstream of RAS, displays two main classes (activating and inactivating) of 
mutations in cancer. The activating mutations consist mainly of V600EBRAF 
(previously deemed as V599E); this mutation of valine to glutamic acid at position 
600 represents 80% of all BRAF mutations in melanomas (Davies et al., 2002) and 
10% of colorectal cancers (Di Nicolantonio et al., 2008). Inactivating mutations on 
BRAF (e.g. G446V, G466E and D594V) are also found in cancers, despite them 
being catalytic and biologically inactive. It is thought that inactive BRAF (D594VBRAF 
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for example) cooperates with oncogenic RAS and CRAF to promote tumor 
progression (Heidorn et al., 2010). 
While the RTK-RAS-RAF pathway is frequently found mutated in cancers and 
play an important role in tumor initiation, it is probably dispensable for the 
maintenance of tumors. Using a series of different RAS mutants that activate specific 
effector pathways, Lim and Counter elegantly showed that the RAS-PI3K-AKT axis, 
as opposed to both RAS-RAF-ERK and RAS-RalGEF, is sufficient and essential for 
tumor cell growth and maintenance ((Lim and Counter, 2005) and reviewed in 
(Downward, 2008)). 
Currently, research into the role of growth factors in cancer is lacking, with more 
emphasis placed on the understanding of their receptors and downstream effectors 
instead. Nonetheless, unbridled autocrine and paracrine signaling by growth factors 
such as FGFs also contribute to oncogenic signaling (reviewed in (Turner and Grose, 
2010)). Amplification of FGF1 has been reported in ovarian cancers (Birrer et al., 
2007; Smith et al., 2012), with paracrine FGF1 facilitating angiogenesis (Birrer et al., 
2007). In gastric cancers, FGF7 (or Keratinocyte Growth Factor (KGF)) protein and 
transcript has been found upregulated in fibroblasts (Nakazawa et al., 2003), 
contributing to cancer cell proliferation in a paracrine manner. FGF1 and FGF7 have 
been suggested as prognostic markers, with both showing negative correlations with 
patient survival (Toyokawa et al., 2009) or cisplatin treatment (Smith et al., 2012). It 




1.3 RTK pathway – Themes of regulation 
In the normal cell, signal transduction pathways like the RTK-MAPK must be 
placed under tight regulatory scrutiny to prevent abnormal cell signaling. However, 
there are many layers of complexity in RTK-MAPK signaling. To achieve specificity 
in RTK signaling action, several mechanisms are used. 
1.3.1 Protein Scaffolds and adaptors 
The first theme of RTK-MAPK signal regulation is the utility of scaffolding 
proteins. The pathway has several such scaffolds to ensure specificity and precision of 
signaling by compartmentalizing signaling (reviewed in (Brown and Sacks, 2009; 
Meister et al., 2013)). For examples, Kinase suppressor of Ras-1 (KSR) localizes 
ERK signaling to the plasma membrane (Koveal et al., 2012); Similar Expression to 
FGF (SEF) facilitates signaling at the cytoplasm (Duhamel et al., 2012; Torii et al., 
2004); MEK-partner 1 (MP1) localizes MEK/ERK signaling to endosomes 
((Schaeffer, 1998), and reviewed in (Brown and Sacks, 2009)) and Paxillin directs 
MAPK signaling at focal adhesions (Rosse et al., 2012). Other scaffolds include β-
arrestin, IQGAP1 (reviewed in (Brown and Sacks, 2009)) and others. 
1.3.2 Intermolecular interactions and protein domains 
The second recurring theme in RTK-ERK pathway regulation is functional 
intermolecular interactions. Proteins carry out their functions in signaling modules or 
complexes. Protein-protein interations therefore determine specificity of action. 
Protein-binding domains such as the ones depicted Figure 1.3 are central to 
intermolecular interactions. These highly conserved motifs recognize sequences or 
post-translational modifications on target proteins. For example, SH2 and Phospho-
Tyrosine Binding (PTB) domains recognize phosphorylated tyrosine residues. SH3 
domain recognizes proline-rich domains. Due to the highly predictable functions of 
these domains, they are thought to be the essential building blocks of proteins 
(reviewed in (Seet et al., 2006)). 
Scaffolds and adaptor proteins in the RTK-ERK pathway are frequently found to 
have several protein interaction domains. For instances, Grb2 has one SH2 domain 
and two SH3 domains; PTB domains are found on the adaptor FRS2; and KSR 
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contains a 14-3-3 binding domain. Due to the highly conserved functions of these 
protein domains, biochemical properties of proteins may be predicted through “guilt-
by-association” of these domains on the proteins of interest. This can now be 
facilitated with online bioinformatics tools like Pfam, querying for interaction 
domains on proteins of interest (Punta et al., 2011).   
 
 
Figure 1.3 Protein interaction domains (adapted from (Pawson, 2003)). These highly 
conserved domains recognize specific residues, post-translationally modified residues 
or amino acid/ lipid sequences.  
 
1.3.3 Feedback regulators 
The third theme, feedback regulation, adds an additional layer of control and 
possibly fine-tuning to cell signaling. Parallels may be drawn between signal 
transduction pathways and electrical circuitry (Illustrated in Figure 1.4). Both 
biochemical and electrical signals travel along defined pathways. The main signaling 
components are likened to relays, communicating signals from one to another. 
Inhibitory proteins are like resistors, reducing the signal output; scaffolding proteins 
are similar to transistors and capacitors, amplifying or switching the signal with 
specificity. While scaffolds and adaptors facilitate signaling, feedback regulators are 
also an essential component of both cellular and electrical signal pathways.  
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Unlike the simplistic model presented in Figure 1.4, feedback regulators are also 
regulated by network inputs and subject to mechanistic controls. As the expression 
and/or of these feedback regulators are promoted by upstream signaling events, they 
are able to act as sensors to regulate signaling outcomes. One example of an RTK-
ERK pathway feedback regulator is the Sprouty family of proteins, which is the main 
focus of work presented in this thesis. 
 
Figure 1.4 A simple electrical circuit with feedback (adapted from 
www.answers.com/topic/feedback, protein names added for illustrative purposes). 
FGF is similar to an electrical input signal – it activates the pathway. Downstream of 
electrical input signals are amplifiers, which transduce signals. Amplifiers parallel 
what downstream signaling proteins like RAS and MAP kinases do in biochemical 
pathways. Feedback networks regulate the input signal in order to fine-tune the output 




1.4 Sprouty family in development and disease 
Sprouty (Spry) was first characterized by Hacohen and colleagues as an antagonist 
of FGF signaling that governs lung tracheal branching in Drosophila (Hacohen et al., 
1998). In a genetic mutant screen, they reported that a mutant gene gave rise to hyper-
sprouting of Drosophila lung tracheal branching, hence the name of the gene, 
Sprouty. Spry loss of function mutations augmented Branchless (Bnl) (homolog of the 
human FGF) mediated branching with a corresponding increase in expression of Bnl 
target genes. Bnl mutants also failed to express Spry and the converse is true, with 
constitutive expression of Bnl leading to widespread expression of Spry in the lung 
branch system. The authors also demonstrated that Spry expression is activated by Bnl 
signaling, suggesting that Spry negatively feeds-back on Bnl signaling. 
Subsequently Casci et al. reported that the action of Spry was not limited to FGF 
signaling (Casci et al., 1999). In Drosophila genetic screens, they showed that Spry 
antagonizes other RTKs, such as Torso and Sevenless. The human homologs of Torso 
and Sevenless are unknown although Torso shares similarities with human growth-
factor-activated RTKs (www.sdbonline.org/fly/torstoll/torso1.htm). Casci and 
colleagues went further to establish Spry as a general inhibitor of Ras signal 
transduction. 
The role of Spry as an RTK-RAS inhibitor is evolutionarily conserved, with its 
inhibitory function on the pathway also observed in mammalian systems. The 
mammalian Sprouty (Spry) family consists of 4 members, Spry1 through 4. Spry1, 2 
and 4 are ubiquitously expressed in the embryo and adult tissues. Spry3 expression is 
restricted to the brain and testis. In Human Embryonic Kidney 293 (HEK 293) cells, 
Spry2 and Spry4 expressions are induced by FGF and EGF stimulation (Sasaki et al., 
2001), similar to observations by Hacohen et al. that dSpry expression is triggered by 
Bnl signaling (Hacohen et al., 1998). Among Spry1, 2 and 4, Spry2 is the most potent 
biochemical inhibitor of FGF-ERK signaling (Lao et al., 2006), acting on the pathway 
at the level of Grb2/SOS (Lao et al., 2007) and RAF (Yusoff et al., 2002) (Illustrated 
in Figure 1.5).  
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Figure 1.5 Spry2 inhibits the FGF-RAS-ERK pathway (figure by Daniel Yim). 
 
Aberrant Spry2 expression has been found associated with a diverse range of 
developmental phenotypes. For example, Spry2 double knockout mice had diastemic 
teeth (diastema is a space between two teeth) and abnormally thick and long 
mandibular incisors that resemble tusks. Spry1 double knockout mice had defects in 
kidney development. Spry4 double knockout mice that survived after birth displayed 
growth retardation. Many of these phenotypes were attributed to RTK signaling such 
as the Glial cell line-Derived Neurotrophic Factor/Rearranged during Transfection 
(GDNF/RET), FGF/FGFR, EGF and VEGF pathways (reviewed in (Guy et al., 
2009)). The fact that Spry2 inhibited FGF-ERK signaling better than Spry1 and 4, but 
loss of function of the latter two gave more profound phenotypes hints to the 
possibility that Spry isoforms may have different regulatory potencies in distinct 
pathways and the function of Spry proteins is not limited to the FGF-ERK axis. 
Developmental processes require precise control over signaling outputs and Spry 
proteins are able to elicit fine-tuning of these developmental pathways, as suggested 
by work from the Gail Lab. Metzger et al. deciphered the complete three-dimensional 
branching lineage of the lung bronchial network in the mouse (Metzger et al., 2008). 
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They went on to report that loss of Spry2 gave local and subtle effects on branch 
patterning and lineage. As a result of Spry2 absence, regions along parent tracheal 
branches begin to acquire branching typical of more distal regions. Defining lung 
airway shape as the quotient of average tube circumference and length, Tang et al. 
showed quantitatively that double knockouts (DKO) of Spry1 and Spry2 resulted in 
abnormal changes in lung airway tube changes (comparing 47 and 36 somite-staged 
mouse embryos), with a corresponding increase in ERK1/2 activity. The authors went 
further to present a quantitative relation between airway shape changes and mitotic 
spindle angle distribution, and found that spindle angles were aberrant in Spry1/2 
DKO. Since heterozygous deletion of FGF10 was sufficient to rescue the Spry1/2 
DKO phenotype, Tang et al. suggest that Spry1 and 2 influences FGF10-ERK1/2 
signaling and mitotic spindle orientation for intricate control over lung airway tube 
shape changes in mice (Tang et al., 2011). 
Spry2 functions in morphological processes of neuronal cells as well, serving to 
regulate neurite outgrowths and neuritogenesis. Hausott and colleagues found that 
Small Interfering RNA (siRNA) knockdown of Spry2 in the adult sensory neurons of 
dorsal root ganglia (DRG) results in elongation of axons (Hausott et al., 2009) in a 
RAS-ERK pathway dependent manner. Spry2 was also reported to interact with G 
protein-regulated inducer of neurite outgrowth (GRIN) to disrupt the interaction of 
GRIN with the G protein, Gαο (Hwangpo et al., 2012), suggesting a possible 
mechanism of regulation of Spry2 function in the brain. In the mammalian brain, Gαο 
is the most abundant G protein and Gαο-GRIN interaction positively regulates neurite 
extension and neuronal morphology. 
Besides developmental and neurobiology, Spry is also implicated in cancers. In a 
relatively small sample size (n = 50), Spry1 and Spry2 cDNA levels were found 
downregulated in 78% and 96% of matched normal-tumor samples respectively, and 
50% of the samples displayed elevated levels of ErbB2 (HER2) (Lo et al., 2004). 
Although the authors did not establish a link between Spry1/2 and ErbB2 transcript 
levels, data seem to suggest that Spry2 transcript is downregulated in samples that 
display elevated ErbB2 (Lo et al., 2004). Faratian et al. reported a similar inverse 
correlation a between Spry2 and ErbB2 expression in a meta-analysis of 1,107 
primary breast cancers gene expression microarray (Faratian et al., 2011). Spry2 is 
also downregulated in hepatocarcinomas. 92% of matched normal-liver tumor cell 
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lines (n = 75) and 73% of matched normal-tumor tissues (n = 11) displayed 
downregulation of Spry2 (Fong et al., 2006). In prostate cancers, SPRY2 were found 
epigenetically inactivated (McKie et al., 2005). Spry2 loss is suggested to hyper-
activate ErbB2-PI3K/AKT signaling (Gao et al., 2012) or cooperate with Phosphatase 
and Tensin Homolog (PTEN) and Protein Phosphatase 2A (PP2A) inactivation to 
promote prostate tumor progression (Patel et al., 2013). Thus, Spry proteins are 
thought to be tumor suppressors. 
Notably, recent data suggest that Spry2 may have oncogenic roles. In colon cancer 
cells lines, Spry2 protein levels inversely correlated with that of E-cadherin. Spry2 
was thought to depress E-cadherin levels through ZEB1, thus promoting epithelial-
mesenchymal transition (Barbáchano et al., 2010). Additionally, Spry2 may facilitate 
metastasis through cooperation with c-Met (Holgren et al., 2010). Spry2 was also 
found to correlate with poor prognosis in colon carcinoma patients (Ordóñez-Morán 
et al., 2013). SPRY2 expression was upregulated by β-catenin/FOXO3a, with a 
corresponding increase in EGFR/ERK-AKT signaling in colorectal cancer cell lines 
(Ordóñez-Morán et al., 2013).  
A possible explanation for the discrepancy in the role of Spry2 in cancer could be 
found in the pathway specific roles of Spry2. As Spry2 has been shown to potentiate 
EGF-ERK signaling (Sasaki et al., 2001; Wong et al., 2002) while inhibiting other 
RTK-RAS-ERK pathways (Casci et al., 1999; Hanafusa et al., 2002; Yusoff et al., 
2002) as well as ErbB2-PI3K/AKT signaling (Gao et al., 2012), Spry2 may play 
tumor suppressive or oncogenic roles depending on what pathways are driving 
oncogenesis. Furthermore, it is not yet known if Spry2 are mutated in these cancers, 
which may result in aberrant function.  
Spry proteins have important functions in physiology and disease. Given the roles 




1.5 Sprouty2 biochemistry 
Unlike Grb2 and KSR, Spry proteins are nearly devoid of common/classic protein 
interaction motifs depicted in figure 1.3. However, the Spry isoforms share at least 
three conserved regions (Figure 1.6 and 1.7) that contribute to function. First, at the 
N-terminal lies the canonical Casitas B-lineage lymphoma (c-Cbl) tyrosine kinase-
binding (TKB) motif that contains a critical tyrosine residue. This residue corresponds 
to tyrosine 55 on Spry2 (Y55Spry2). Second is the cysteine-rich domain (CRD) or 
otherwise known as the (Sprouty/Spred) SPR domain. Third is the Serine/Threonine 
rich (STR) region, otherwise known as serine rich motif (SRM). Spry2 is unique from 
the rest of the isoforms, as it possesses an additional PxxPxR motif at its C-terminus. 
This proline motif is responsible for binding to the SH3 domain of Grb2 (Lao et al., 
2006). All these domains are an integral part of Spry2 mechanism of action. In 
elucidating the biochemistry of the Sprouty proteins, the themes of RTK pathway 
regulation mentioned in the earlier section are revisited. 
 
Figure 1.6 The schematic representation of domain organization on Spry2 (figure by 
Daniel Yim). Spry2 share three conserved domains – the 50-60 region that binds c-
Cbl, the serine/threonine rich region and the cysteine rich domain, with other Spry 
isoforms. Spry2 also contains a unique C-terminal Grb2 binding domain. 
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Figure 1.7 Sequence conservation and domain organization of human Spry family 
(alignment generated by Daniel Yim for (Guy et al., 2009)). In red highlight: the 50-
60 region that binds c-Cbl. Green highlight: the serine/threonine rich region and in 
blue highlight: the cysteine rich domain. In pink: the unique C-terminal Grb2 binding 
domain on Spry2. 
 
1.5.1 Sprouty localization 
Firstly, plasma membrane localization of Spry2 is essential for its FGF-ERK 
inhibitory capacity (Casci et al., 1999; Lim et al., 2002). Spry translocates to the cell 
membrane upon growth factor stimulation (Lim et al., 2000) and the CRD domain 
facilitates this process, either through palmitoylation (Impagnatiello et al., 2001), or 
by targeting phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P2) at the membrane 
(Lim et al., 2002). Notably, a point mutant in the CRD domain, R252DSpry2, both 
abolished binding to PtdIns(4,5)P2, as well FGF-ERK inhibitory function. Spry2 
associates with microtubules but the exact mechanism(s) of Spry2 plasma membrane 
translocation (e.g. the motor proteins involved) is not known. It is postulated that 
Spry2 binds Grb2 at the plasma membranes when FGF signaling is activated 
(Hanafusa et al., 2002), sequestering Grb2 from SOS (Lao et al., 2006), thus 
preventing upstream signals from transducing. 
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1.5.2 Intermolecular interactions of Sprouty  
Secondly, the intermolecular interactions of Spry2 determine its specificity of 
action. For instances, Spry2 association with c-Cbl potentiates EGF-ERK signaling 
(Wong and Guy, 2006); PP2A binding and action on Spry2 has been reported to 
regulate Spry2-Grb2 binding (Lao et al., 2007), and consequently Spry2-Grb2 
interaction is necessary for Spry2 inhibitory action of FGF-ERK signaling (Hanafusa 
et al., 2002; Lao et al., 2006). PP2A and c-Cbl competes for binding on the same 
region of Spry2 (aa 50-60) (Lao et al., 2006), suggesting that distinct Spry2-
interactant pools exist to facilitate different signaling outcomes. 
1.5.3 Phosphorylation of Sprouty 
Thirdly, phosphorylation of Spry governs its intermolecular interactions. Tyrosine 
phosphorylation of residue 55 on Spry2 and the corresponding residue 53 on Spry4, 
by Sarcoma (Src) (Li et al., 2004) or other yet uncharacterized tyrosine kinases, 
creates a binding motif for the TKB domain of c-Cbl: N-X-pY-S/T-X-X-P (Ng et al., 
2008). C-Cbl is an E3 ubiquitin ligase that targets proteins for ubiquitination leading 
to proteasomal degradation (Ng et al., 2008; Wong and Guy, 2006). Spry2 binding 
was postulated to sequester c-Cbl from the EGFR complex, preventing c-Cbl 
mediated EGFR protein degradation in the process and thus sustaining EGF-ERK 
signaling (Wong and Guy, 2006). 
The Guy lab suggests alternatives of the physiological roles of Spry2-Cbl 
interaction, as the work by Wong et al. were conducted using supra-physiologic levels 
of Spry2. Firstly, Spry2 itself may be a target of c-Cbl mediated ubiquitination. 
Secondly, Spry2 may facilitate ubiquitination by c-Cbl to interacting proteins. Lastly, 
Spry2 could play the role of an adaptor for c-Cbl (Guy et al., 2009). Nonetheless, 
Y55Spry2 or Y53Spry4 is important regulatory residue for Spry2 function, with point 
mutations of the tyrosine abrogating Spry inhibitory function in FGF-ERK pathway 
(Lao et al., 2006; Sasaki et al., 2001).  
S/T phosphorylation of Spry2 is as important as its tyrosine phosphorylation. 
Phospho-amino acid analysis indicated that Spry2 is phosphorylated primarily on 
serine residues and 32P-orthophosphate incorporation into Spry2 did not change 
markedly with FGF stimulation (Impagnatiello et al., 2001). However, mass 
spectrometry analysis revealed a significant change in the phosphorylation profiles 
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between resting-state Spry2 and FGFR1-activated Spry2 (Lao et al., 2007). An 
increase in phosphorylations was observed with a subset of residues 
dephosphorylated. Lao et al. also further demonstrated that okadaic acid (a PP2A/PP1 
selective inhibitor) treatment disrupted Spry2-Grb2 interaction. 
Spry2-Grb2 interaction is essential for Spry2 to inhibit FGF-ERK signaling. The 
Grb2 SH3 domain binds to a C-terminal PxxPxR motif that is unique to Spry2 among 
the Spry isoforms (Figure 1.7).  Using a chimeric Spry4 protein with the Spry2 
PxxPxR motif (Spry4-PxxPxR), Lao et al. established that the PxxPxR motif is 
sufficient for Grb2 binding. Moreover, Spry4-PxxPxR inhibited FGFR1-ERK 
signaling, unlike wildtype Spry4 (Lao et al., 2006), indicating that the PxxPxR motif 
and Grb2 binding is necessary and sufficient for the FGF-ERK inhibitory capacity of 
Spry2. The fact that Grb2 only interacts with Spry2 upon FGFR1 activation suggest 
that the PxxPxR motif is masked in resting state Spry2 (Lao et al., 2006). 
The residues 50-60 flanking Y55Spry2 was found to influence binding to Grb2 
(Lao et al., 2007). Both PP2A and c-Cbl was reported to compete for Spry2 binding in 
this region. Deletion of residues 50-60 resulted in loss of PP2A and c-Cbl binding to 
Spry2, with a corresponding loss of Spry2-Grb2 binding. Lao et al. proposed that 
Spry2-PP2A and Spry2-c-Cbl exist as 2 distinct complexes. C-Cbl docks to Spry2 to 
mediate ubiquitination leading to proteasomal degradation (Wong et al., 2002), 
whereas PP2A binding to and dephosphorylation of Spry2 facilitates changes in 
protein tertiary structure necessary to reveal the PxxPxR motif needed for Grb2 
interaction. However, whether phosphorylation on Y55Spry is required for its 
interaction with PP2A is still unknown (Lao et al., 2007). 
  
 18 
1.6 Sprouty2 and serine/threonine kinases 
Along with the global changes in phosphorylations on Spry2 during signaling, 
PP2A interaction with Spry2 was enhanced during FGFR1 activation (Lao et al., 
2007). Lao and colleagues found that S112 and S115 were dephosphorylated possibly 
by PP2A, amid stable phosphorylation on other residues. Perturbing this 
phosphorylation balance by okadaic acid, an S/T phosphatase inhibitor resulted in the 
abrogation of Spry2 binding to Grb2. This suggests both S/T kinases are likely to act 
in tandem with PP2A (or other S/T phosphatases) to achieve a fine balance of 
phosphorylation changes necessary for Spry2-Grb2 interaction and inhibition of FGF-
ERK signaling. 
These changes in S/T phosphorylation may be manifested in Spry2 electrophoretic 
mobility shifts. The Spry2 protein migrates on SDS PAGE as two major bands and 
evidence indicates that the slower migrating band is the consequence of 
phosphorylation as alkaline phosphatase treatment results in the disappearance of that 
band (Impagnatiello et al., 2001; Lao et al., 2007). Lao and team also found that 
residues in the STR motif (residues 107-134) govern the slower migrating band 
(details in a later section). In addition, treatment of cultured cells with okadaic acid 
induced Spry2 band shifts in favor of the slower migrating band. Several S/T kinases 
have been reported to phosphorylate Spry2, and in so doing, modulate Spry2 function. 
The following sections give a summary of findings. 
1.6.1 Mnk1 
One paper reported that Mitogen-activated protein kinase-interacting kinase 1 
(Mnk1) could regulate Spry2 stability. They showed that inhibiting Mnk1 with 
CGP57380 destabilized Spry2, whereas constitutively active Mnk1 mutants promoted 
Spry2 protein stabilization (DaSilva et al., 2006). The authors claim that Mnk1 
phosphorylates Spry2 on residues Ser112 and 121 in the STR region from the 
observation that T332 Mnk1 failed to induce electrophoretic mobility shifts in the 
S112A/S121ASpry2 band. In addition, the S112A and S121A point mutations enhanced 
EGF mediated Spry2-c-Cbl interaction, which is otherwise abolished in the triple 
mutant Y55F/S112A/S121ASpry2. Although S112A/S121ASpry2 displayed sustained FGF-ERK 
signaling compared to wild type Spry2, the authors did not provide direct evidence of 
the role of Mnk1-mediated phosphorylation on Spry2 inhibition in the pathway.  
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1.6.2 DYRK1A 
Another S/T kinase with functional interaction with Spry2 is Dual specificity 
tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) (Aranda et al., 2008). The 
authors presented evidence that DYRK1A inhibits Spry2 activity, thus facilitating 
FGF-ERK signaling. They also showed that endogenous DYRK1A and Spry2 co-
localized in the dendritic processes of cortical neurons. DYRK1A was found to bind 
the cysteine rich domain of Spry2 residues 164-255. 
Co-expression of DYRK1A caused a Spry2 mobility shift in favor of the slower 
migrating band, suggesting that DYRK1A phosphorylates Spry2. Indeed, the authors 
reported that DYRK1A phosphorylates T75 of Spry2. Mutating T75Spry2 to alanine 
resulted in the enhancement of FGF-ERK inhibition, implying that DYRK1A 
phosphorylation of Spry2 inhibits Spry2 function. However, the role of DYRK1A in 
Spry2-Grb2 binding is still unknown. This is the sole report of DYRK1A as a 
negative regulator of Spry2. 
1.6.3 Tesk1  
In addition to DYRK1A, there is one report of Testicular protein kinase 1 (Tesk1) 
as a negative regulator of Spry2 (Chandramouli et al., 2008). Chandramouli et al. 
showed that Tesk1 inhibited Spry2-Grb2 binding, thus abrogating Spry2 inhibition of 
FGF-ERK signaling. The authors also showed that Tesk1 and Spry2 interact 
endogenously, and Tesk1 binds the C-terminus region of Spry2 (residues 165-315). 
Like DYRK1A, Tesk1 induced Spry2 mobility shifts in the presence of FGFR1 
activation, suggesting that Tesk1 phosphorylates Spry2. 
1.6.4 PKCδ 
One report of the fifth S/T kinase interacting with Spry2 is Protein kinase Cδ 
(PKCδ). PKCδ binds Spry2 upon FGFR1 activation and abrogates Spry2 inhibition of 
FGF-ERK signaling (Chow et al., 2009), suggesting the existence of yet another 
antagonist of Spry2.  However, the authors did not address if Spry2-Grb2 binding is 
regulated by PKCδ. 
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1.6.5 Other serine/threonine kinases of Sprouty2 
Besides the above four S/T kinases, there are hints of other Spry2 S/T kinase(s). 
Serines 112 and 115 that are found dephosphorylated upon FGFR1 activation, fit into 
the consensus phosphorylation motif of Casein Kinase 1 (CK1) – pS/T-X-X-S/T; 
where the -3 serine is phosphorylated by a priming kinase (Flotow et al., 1990). Lao 
and colleagues further demonstrated through mutational analysis that serine residues 
in the STR domain are responsible for the slower migrating band (Lao et al., 2007). 
Among these residues, S112, S115, S118, S121, S124, S127, S130 constitute a series 
of CK1 phospho-motifs. A kinase phospho-motif scan also suggest that at least 21 
CK1 sites are found throughout full-length Spry2 (Table 1.1). In fact S167, which was 
found phosphorylated upon FGFR1 activation, matches a variant CK1 consensus 
phospho-motif – S/T-X-X-D/E, where acidic residues lay 2 residues 
upstream/downstream of the target site (Flotow and Roach, 1991). Although Spry2 
contains phospho-motifs of other kinases including Casein Kinase 2 (CK2) and 
Glycogen Synthase Kinase 3 (GSK3), the frequent occurrence of pS/T-X-X-S/T 
(especially in the STR domain) raises the question whether Spry2 is a substrate for 
CK1, and if CK1 is involved in Spry2 regulation.  
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>gi|5032115|ref|NP_005833.1| protein sprouty homolog 2 [Homo sapiens] 
AA Position Peptide Predicted Kinase 
7 RAQSGNG CK1 
101 QVHSSAR GSK3 
108 APLSRSI CK1 
108 APLSRSI GSK3 
110 LSRSIST CK1 
112 RSISTVS CK1 
112 RSISTVS GSK3 
113 SISTVSS CK1 
115 STVSSGS CK1 
116 TVSSGSR CK1 
118 SSGSRSS CK1 
118 SSGSRSS CK2 
118 SSGSRSS GSK3 
120 GSRSSTR CK1 
121 SRSSTRT CK1 
121 SRSSTRT GSK3 
122 RSSTRTS CK1 
124 STRTSTS CK1 
125 TRTSTSS CK1 
126 RTSTSSS CK1 
127 TSTSSSS CK1 
127 TSTSSSS CK2 
128 STSSSSS CK1 
128 STSSSSS CK2 
128 STSSSSS GSK3 
129 TSSSSSE CK1 
129 TSSSSSE CK2 
130 SSSSSEQ CK1 
130 SSSSSEQ CK2 
130 SSSSSEQ GSK3 
131 SSSSEQR CK1 
131 SSSSEQR CK2 
141 SSFSSGP CK1 
156 QPKSELK GSK3 
167 KPLSKED CK1 
167 KPLSKED CK2 
167 KPLSKED GSK3 
230 YHCSNDD CK2 
305 KVPTVPP GSK3 
Table 1.1 Sprouty2 protein sequence queried for kinase phosphorylation motifs of 
CK1, CK2 and GSK3 (csbl.bmb.uga.edu/~ffzhou/gps_web/faq.php). 
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1.7 Casein Kinase 1 
Casein kinase 1 (CK1) is a major cellular S/T kinase with diverse physiologic 
functions. The human CK1 protein kinase family is encoded by six genes (α, γ1, γ2, 
γ3, δ, and ε). CK1 is involved in several signal transduction pathways such as Wnt/β-
catenin and planar cell polarity pathways, Hedgehog signaling, p53 tumor suppressor 
pathway and the circadian rhythm pathway. The role of CK1 in multiple pathways 
highlights its importance in biology.  
1.7.1 Intramolecular regulation of CK1 
CK1α is the smallest (~38 kDa) among the family, and has been thought to be 
constitutively active. CK1δ and CK1ε have similar carboxyl-terminal tails (148-184 
aa) that can be itself substrates for the kinase domain. Thus CK1δ/ε are actively auto-
phosphorylated (Graves and Roach, 1995; Rivers et al., 1998). This gives rise to a 
kinase-phosphorylated tail conformation that sterically hinders protein substrates from 
accessing the active site of the kinase. The intramolecular inhibitory mechanism of 
CK1δ/ε can be relieved through the action of protein phosphatases. These 
phosphatases may relieve CK1δ/ε autoinhibition in response to extracellular signals 
(e.g. glutaminergic (Liu et al., 2002b) and Wnt signaling (Swiatek et al., 2004)). The 
regulation of CK1γ is less clearly defined, as compared to the other CK1 isoforms. 
1.7.2 CK1 interaction and phosphorylation motifs 
Certain substrates of CK1 contain interaction motifs that facilitate binding to the 
kinase. For instance, CK1α and ε recognize the F-X-X-X-F motif found on substrates 
like Nuclear Factor of Activated T-cells (NFAT1) and Period 2 (PER2) (Okamura et 
al., 2004). This motif is distal to phosphorylation sites; the substrate binding to the F-
X-X-X-F motif can stabilizes interaction with the kinase. This enhances enzyme-
substrate proximity, thus facilitating the substrate for access of CK1 to the 
phosphorylation site. 
The F-X-X-X-F motif is also found to be present on other CK1 targets. However 
its essentiality as a CK1 binding motif for substrates in general has not been 
rigorously tested. Other binding motifs may exist. The presence of these scaffold-
binding sites is likely to influence rates of phosphorylation of substrates. 
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In addition to interaction motifs, CK1 also recognizes consensus phosphorylation 
motifs. This adds another level of substrate specificity. As mentioned earlier, CK1 
displays preference for “primed” substrates. The main CK1 phosphorylation motif is 
pS/T-X-X-S/T (Flotow et al., 1990), where the serine in the -3 position is the primed 
phosphorylated site. Besides pS/T-X-X-S/T, CK1 also recognizes clusters of 3-4 
acidic residues (usually Asp) at the -3 position in place of the primed phospho-site 
(Flotow and Roach, 1991). This motif is found on CK1 substrates like β-catenin and 
NFAT (Marin et al., 2003).  
1.7.3 Pharmacological inhibitors and allosteric activators of CK1 
In addition to the regulatory mechanisms mentioned above, drugs and allosteric 
activators can also modify Casein Kinase 1 activity, three of which are presented 
below. 
PF670462 (PF670), a CK1δ/ε pan-selective inhibitor has an in vitro IC50 range of 
80-130 nM (Badura et al., 2007). PF670 delays circadian clocks through the inhibition 
of CK1 in mice. PF670 may have possible therapeutic benefits in the treatment of jet 
lag and other biological clock related disorders (Meng et al., 2010).  
PF4800567 (PF480) is a CK1ε selective inhibitor, with an IC50 of 32 nM. Against 
CK1δ, PF480 has an IC50 of 711 nM. Selective inhibition of CK1ε by PF480 was not 
as effective in inhibiting Wnt/β-catenin TOPFlash signaling as compared to PF670. In 
addition, PF480 had no effects on proliferation of cultured cells (Cheong et al., 2011).  
D4476 is a CK1 inhibitor with IC50 of 0.3 µM. Although the Cohen lab only 
reported its activity against CK1δ, they suggested the use of D4476 against other CK1 
isoforms as well (Rena et al., 2004). There is at least one instance when D4476 was 
used to inhibit CK1α (Honaker and Piwnica-Worms, 2010). 
                           
Figure 1.8 Chemical structures of (L to R) PF670462, PF4800567 (adapted from 
www.millipore.com) and D4476 (Rena et al., 2004). 
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The United States Food and Drug Administration (US FDA) approved drug 
pyrvinium was recently identified as an allosteric activator of CK1α in a screen for 
Wnt/β-catenin pathway inhibitors (Thorne et al., 2010). Although the drug could bind 
other isoforms of CK1, its action is specific for CK1α. The authors went on to show 
that a C-terminal tail truncated mutant of CK1δ could be activated by pyrvinium. 
These findings suggest the existence of a conserved pyrvinium-binding site on CK1. 
Notably, this activation is abrogated by intramolecular action of the C-terminal 
domains of CK1δ/ε. 
 
Figure 1.9 Chemical structure of pyrvinium (adapted from toxnet.nlm.nih.gov). 
 
Allosteric activators of Casein Kinase 1 were uncharacterized until recently, when 
Cruciat et al. reported that the DEAD box RNA helicase DDX3 is a protein allosteric 
activator of CK1 (Cruciat et al., 2013). Other DDX isoforms including DDX4 and 
DDX56 shares the same function as DDX3. The authors reported that DDX3 plays a 
role in Wnt-dependent apical-posterior neural patterning of Xenopus central nervous 
system, as well as neuroblast migration in C. elegans. Furthermore, DDX3 physically 
interacts with CK1ε after Wnt stimulation and is required for Wnt/β-catenin signaling 
in human cell lines. 
The 37 DDX proteins belong to a family of DEAD box RNA helicases. They are 
named “DEAD” because of the Asp-Glu-Ala-Asp amino acid sequence found in their 
motif II. The primary function of DDX family functions is the unwinding of double 
stranded RNA in an ATP dependent manner. The helicase activity of DDX3 is not 
needed in CK1 activation or Wnt signaling. This further suggests auxiliary roles of 
the helicase (reviewed in (Yim and Virshup, 2013)). DDX3 apparently functions at 
the level of Low-density lipoprotein Receptor-related Protein 5/6 (LRP5/6) and works 
with CK1ε to phosphorylate Disheveled. 
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Figure 1.10 Modes of regulation of Casein Kinase 1 (adapted from (Yim and 
Virshup, 2013)). CK1 activity may be regulated intra-molecularly via 
autophosphorylation and autoinhibition of the C-terminal tail. Activating 
phosphatases may work on the C-terminal tail to relieve the autoinhibition. CK1 
activity can also be inhibited by small compounds and activated allosterically by 
proteins such as the DDX family, and compounds like pyrvinium pamoate. Specificity 
and substrate binding, protein localization and priming kinases add another level to 
regulation of CK1 function.  
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1.8 Casein Kinase 1 in physiology and disease 
The circadian rhythm exists to entrain organisms to environmental light-dark 
cycles and CK1ε and δ regulate these biological cycles through phosphorylation of 
the period (PER) proteins. The first mammalian circadian rhythms mutation was 
identified in CK1ε of the tau hamster (reviewed in (Gallego and Virshup, 2007)). The 
tau gain of function mutation of CK1ε results in circadian cycle shortening to 20 
hours (Meng et al., 2008). However, the role of CK1ε in circadian rhythms is 
overshadowed by CK1δ. Using genetic knockouts coupled with selective 
pharmacological inhibition of CK1ε and δ (using PF670 and PF480 described above), 
Meng et al. established CK1δ as the major regulator of the circadian clock (Meng et 
al., 2010).  
Arguably, the disease that CK1δ/ε has been best characterized in is the Familial 
Advanced Sleep Phase Syndrome (FASPS) (reviewed in (Gallego and Virshup, 
2007)). FASPS, an autosomal inherited sleep disorder, is an extreme example 
circadian rhythm disorder whereby affected individuals display a 4-5 hour phase 
advance. Thus, these individuals wake up very early in the morning and go to sleep 
very early in the evening. In FASPS, T44 on CK1δ is mutated (Xu et al., 2005), in 
addition to mutations in the CK1 phospho-priming residue on PER2 (Toh, 2001). 
Interestingly, T44ACK1δ was also found associated with increased occurrence of 
migraines in humans, and as a possible mechanism this mutation correlated with 
hyperactive Ca2+ signaling in astrocytes in mice (Brennan et al., 2013). 
CK1δ/ε through their roles in activating β-catenin signaling, inhibiting apoptosis 
and mitosis amongst other physiological roles, have been associated with various 
cancers. Brockschmidt et al. found that expression of CK1δ/ε is upregulated in 
pancreatic tumor cell lines (Brockschmidt et al., 2008). The Hahn Lab subsequently 
reported that CK1ε is required for the proliferation of breast cancer cell lines with 
active β-catenin (Kim et al., 2010). Grueneberg and colleagues identified through 
shRNA screening in HeLa and HEK293T cell lines, CK1ε as a factor in cell 
proliferation and survival (Grueneberg et al., 2008). 
In addition to cancer and sleep disorders, CK1 is also implicated in 
neurodegenerative disease. CK1δ mRNA is found upregulated in Alzheimer’s disease 
brain samples (Schwab et al., 2000). This phenomenon is closely correlated with tau 
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(not to be confused with the CK1ε tau mutation mentioned above). The tau proteins 
are found mainly in neurons of the central nervous system. They are one of the 
microtubule-associated proteins (MAPs) that function to regulate axonal microtubule 
stability. Tau is found to be active in the distal ends of axons and its function can be 
governed by phosphorylation. The positively charged C-terminus of tau binds 
favorably to and stabilizes negatively charged microtubules. Phosphorylation of Tau 
proteins inhibits this process, disrupting microtubule organization. In many 
tauopathies (neurodegenerative diseases caused by abnormal aggregation of Tau 
proteins) such as Alzheimer’s disease and Pick’s disease, Tau is hyper phosphorylated 
(Nussbaum et al., 2012; Schwab et al., 2000). 
Along with Tau-associated intraneuronal neurofibrillary tangles, extracellular 
plaques formed by amyloid-β are histological hallmarks of Alzheimer’s disease 
(Nussbaum et al., 2012). Amyloid-β is the product of the cleavage of amyloid 
precursor protein (APP) by β-secretase (an aspartyl protease) and/or γ-secretase. The 
amyloid-β fibril plaques form mono- or oligo-meric structures, of which oligomeric 
intermediates are thought to be toxic and frequently associated with microtubule loss, 
cytotoxicity and neurite degeneration. CK1 was reported to phosphorylate γ-secretase 
to facilitate subsequent cleavage of APP (Flajolet et al., 2007). Overexpression of 
CK1ε or its tail-truncated mutant results in accumulation of amyloid-β in the N2A 
mouse neuroblastoma cell line.  
Besides CK1, many other kinases including GSK3β, Cdk5 and tau-tubulin kinase 
(TTBK) phosphorylate Tau (reviewed in (Dolan and Johnson, 2010)). Unless we have 
a clearer understanding of how the kinome functions in Alzheimer’s disease (or 
tauopathies), the efficiency of CK1 therapeutic modulation is highly debatable.  
 28 
1.9 Pathways in neurite outgrowth 
Receptor tyrosine kinases have also been implicated in neurotropic signaling. For 
instance, NGF (nerve growth factor) activates neuritogenic pathways via 
Tropomyosin Receptor Kinase (Trk) receptors. NGF-Trk signaling triggers 
downstream pathways including the RAS-ERK cascade, PI3K and Phospholipase Cγ 
(PLCγ) (reviewed in (Aloe et al., 2012)). Other reports have indicated that other 
RTKs can promote neurite outgrowth too. Ret receptors respond to GDNF to induce 
neurite outgrowth in Neuro2A cells (Crowder, 2004). 
Cell culture models like the Pheochromocytoma 12 (PC12) cell line (in addition to 
Neuro2A cells mentioned above) are frequently used to study neurite outgrowth 
processes. The PC12 cell line was established from a single cell clone derived from 
transplantable rat adrenal pheochromocytoma (Greene and Tischler, 1976). This 
clonal line stops dividing and differentiates when treated with growth factors like 
NGF and FGF (Hausott et al., 2009).  
Spry2 has been reported to be an inhibitor of NGF and FGF induced neurite 
outgrowth of PC12 cells (Hausott et al., 2009; Wong et al., 2002). Hausott et al. 
showed that Sprouty1 and 2 transcript levels increased significantly after 4 days of 
NGF/FGF stimulation of PC12 cells (Hausott et al., 2009). Spry2 siRNA knockdown 
enhanced axonal growth in adult sensory neurons, in response to FGF stimulation, 
with a corresponding increase in phosphorylated ERK and RAS-GTP protein levels 
(Hausott et al., 2009). The Guy lab also provided evidence to show that Spry2 and not 
Spry4 overexpression in PC12 cells abrogated FGF induced neurite outgrowth (Lao et 
al., 2007).  
Apparently not all growth factors stimulate neurite outgrowth in PC12 cells. EGF 
and insulin are both able to activate RAS-ERK signaling as with NGF and FGF, but 
yet are unable to bring about the same phenotypes. EGF and insulin are weak 
activators of ERK in PC12 cells. On the contrary, NGF and to a lesser extent FGF, 
gives a prolonged signal to ERK. This strong and prolonged signal enables ERK to 
translocate into the nucleus. Thus, the prevailing hypothesis for this phenomenon is 
that neuroblasts/neuronal cultures respond to weak and transient signals to bring about 
cell division. Strong and prolonged activation of ERK will result in triggering of 
neuronal differentiation processes (reviewed in (Avraham and Yarden, 2011)). 
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In addition to growth factors, other mitogens and morphogens may induce neurite 
outgrowth processes. The Rubin lab also reported the role of Wnt3a-induced neurite 
outgrowth in Ewing sarcoma family tumor cells. In two separate reports, they 
implicated the kinases CK1δ and PKCι in mediating this Wnt3a dependent process 
(Greer and Rubin, 2011; Greer et al., 2013). Greer et al. reported that knockdown of 
CK1δ but not CK1ε inhibited Wnt-3A induced neurite outgrowth. CK1ε knockout 
however, increased neurite outgrowths even in the absence of stimuli (Greer and 
Rubin, 2011). It will be interesting to see if the role of CK1ε/δ in NGF/FGF mediated 
neurite outgrowth in PC12 cells share similarities with that in Wnt3A mediated 
processes in Ewing sarcoma cells.  
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1.10 Hypothesis and aims of research 
In this thesis, I investigate the role of CK1 in Spry2 biochemistry and function. In 
testing the hypothesis that CK1 is a kinase that regulates Spry2, the following 
questions need to be addressed: 
Firstly, does CK1 play a role in the FGF-Spry2-ERK axis? Is CK1 required for 
Spry2 inhibition of FGF-ERK signaling? I used CK1 inhibitors such as PF760 to 
answer these questions, and observe if PF670 treated Spry2 is able to inhibit FGF-
ERK signaling. 
Secondly, if CK1 regulates Spry2 function in the FGF-ERK pathway, is this due 
to direct interaction with, and/or phosphorylation of, Spry2? I test this by first 
generating a loss-of-CK1-binding Spry2 mutant and ask if that mutant still retains the 
functions of the wildtype. 
Thirdly, if the FGF-ERK inhibitory capacity of Spry2 is governed by CK1 is CK1 
modulating Spry2-Grb2 interaction? Also, does the role of CK1 extend to other 
functions of Spry2, for instances, Spry2 membrane translocation and Spry2-c-Cbl 
interaction? I used CK1 pharmacological inhibitors, as well as Spry2 loss-of-CK1-
binding mutants to find answers to these questions. 
Fourthly, does Spry2 require CK1 for the inhibition of NGF/FGF induced neurite 
outgrowth? I predicted that loss of CK1 activity renders Spry2 ineffective in 
inhibiting neurite outgrowth in PC12 cells if CK1 is the kinase that governs Spry2 
activity. 
Finally, if CK1 is indeed a kinase regulating Spry2, what is the outcome of this 
interaction in relation to human diseases?  
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Chapter 2. MATERIALS AND METHODS 
2.1 Plasmids 
The wild type, full-length constructs of Spry1, 2 and 4 are cloned into the 
mammalian expression vector pXJ40-FLAG (courtesy of Prof. E. Manser, A*STAR 
IMCB/IMB). The wild type Spry constructs, mutant Spry2 constructs (Spry2Δ50-60, 
Spry2 1-179, Spry2 179-315, Spry2 1-191, Spry2 192-315) and pRK4-FGFR1 have 
been described previously (Fong et al., 2006; Lao et al., 2007; Yusoff et al., 2002) or 
had been generated by the Graeme Guy lab prior to the commencement of work for 
this thesis. 
The following plasmids used for work in this thesis were obtained from the David 
Virshup lab plasmid repository: CK1α-3HA in pcDNA3 (V398), CK1δ-myc in pCS2 
(V1214), CK1δ K38A-myc in pCS2 (V1235), 4HA-CK1ε in pCEP4 (V405) and 
4HA-CK1ε 1-349 in pCEP4 (V743).  
Mutagenesis was conducted on wild type Spry2 in pXJ40-FLAG expression 
vector to generate various truncation, deletion, and serine to alanine point mutants 
reported in this thesis (excluding the ones mentioned above).  
CK1ε was cloned into the PXJ40-HA vector (courtesy of Prof. E. Manser, 
A*STAR IMCB/IMB), and site directed mutagenesis conducted to generate the CK1ε 
D128N-HA construct. 
The HA-GSK3β in pcDNA3 construct was purchased from Addgene, Cambridge 
MA (ID: 14753). The ERK2-Flag, DYRK1A in PXJ40-HA and TESK1 in pCAG-
myc constructs were previously described in (Yusoff et al., 2002), (Li et al., 2010), 




Table 2.1 below lists the primary antibodies used in this thesis. 
Table 2.1 Primary antibodies 
Antigen Host Company/Supplier Cat no. Dilution 
Phospho-p44/42 ERK1/2 Mouse Cell Signaling Technologies 9106 1:1250 
panERK Mouse BD Transduction Labs 610124 1:800 
Spry2 (N) Rabbit Sigma S-1444 1:800 
CK1α C-terminus Rabbit David Virshup Lab/Utah UT3 1:3000 
CK1δ  Mouse Eli Lilly 128A 1:3000 
CK1ε (H-60) Rabbit Santa Cruz Biotechnology SC25423 1:800 
CK1ε Mouse BD Transduction Labs 610446 1:800 
FGFR1 (C15) Rabbit Santa Cruz Biotechnology SC121 1:800 
hDvl2 (H-75) Rabbit Santa Cruz Biotechnology SC13974 1:800 
cMyc (A-14) Rabbit Santa Cruz Biotechnology SC25423 1:800 
Cortactin (H-19) Rabbit Santa Cruz Biotechnology SC11408 1:50 (IF) 
Grb2 (C-23) Rabbit Santa Cruz Biotechnology SC255 1:800 
β-actin Mouse Abcam ab3280 1:1250 
Flag-tag Mouse Sigma F3165 1:3000 
Flag-tag Rabbit Sigma 030M4800 1:1250; 
1:50 (IF) 
HA-tag Mouse Sigma H9658 1:3000 
HA-tag Rabbit Sigma 029K4788 1:1250 
Beta tubulin Cy3 Mouse Sigma C4585 1:500 (IF) 
 
Table 2.2 below lists the secondary antibodies used in this thesis 
Table 2.2 Secondary antibodies 
Antigen Host Company/Supplier Catalog no. Dilution 
IgG peroxidase Mouse Sigma A4416 1:3000 
IgG peroxidase Rabbit Sigma A4914 1:3000 
IgG DylightTM 680 Mouse Thermo Scientific 35518 1:10000 
IgG DylightTM 800 Mouse Thermo Scientific 35521 1:10000 
IgG DylightTM 680 Rabbit Thermo Scientific 35568 1:10000 
IgG DylightTM 800 Rabbit Thermo Scientific 35571 1:10000 
AlexaFluor 488 Mouse Life Technologies A11001 1:50 (IF) 
AlexaFluor 488 Rabbit Life Technologies A11008 1:50 (IF) 
AlexaFluor 594 Mouse Life Technologies A11005 1:50 (IF) 




2.3 Cell culture reagents 
Table 2.3 below lists the various growth factors and pharmacological agents used 
in this thesis. 
Table 2.3 Cell culture reagents 
Growth factors Drugs 
NGF (Sigma N0513) DMSO (Sigma D2650) 
Basic FGF (Sigma Aldrich F0291) PF670462 (Tocris Bioscience 3316) 
 PF4800567 (Pfizer) 
D4476 (Sigma-Aldrich 301836-43-1) 




2.4 Cell culture and transfection 
HEK 293, PC12 and CV-1 (simian) in Origin, SV40 carrying (COS-1) cells were 
purchased from ATCC.  
HEK 293 cells were cultured in Roswell Park Memorial Institute (RPMI) media 
supplemented with 10% volume fetal bovine serum (FBS) and L-glutamine. PC12 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) media with 4.5 
g/L glucose, supplemented with 10% FBS, 5% heat-inactivated horse serum (HS) and 
L-glutamine. COS-1 cells were cultured in DMEM media with 4.5 g/L glucose, 
supplemented with 10% FBS, L-glutamine and sodium pyruvate. 
Plasmid DNA transfections were carried out according to the recommended 
protocol using Lipofectamine 2000 (Invitrogen 11668-019) as transfection reagent 
and OptiMEM (Invitrogen 31985-070) as transfection media. Transfected plasmid 
DNA are expressed in the cells for 16-18 hrs post transfection in 10% FBS. 
Small interfering RNA (siRNA) from Dharmacon against CK1α, δ, or ε were 
transfected with DharmaFECT 1 (Thermo Scientific #T-2001-03) according to the 
recommended protocol. The siRNAs are incubated with cells for three days, or two 
days if experiment requires subsequent transfection of plasmid DNA. 
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2.5 Protein methodology 
2.5.1 Preparation of protein extracts from cultured cells 
Cultured cells were rinsed with cold phosphate buffered saline (PBS) prior to cell 
lysis. Excess PBS/ culture media are removed before cells were lysed in cold HEPES 
lysis buffer [20 mM HEPES (pH 7.5); 137 mM NaCl; 1% Triton X-100; 10% 
Glycerol; 1.5 mM MgCl2; 1 mM EGTA; 1x concentration of Complete protease 
inhibitor cocktail (Roche, Mannheim, FRG); 0.2 mM sodium orthovanadate 
(Na3VO4); and 1 mM Dithiothreitol (DTT)]. The lysates were collected by manually 
using a cell scraper. Whole cell lysates were clarified through 13000 rpm 
centrifugation at 4 °C for 15 min. The cell lysates were collected for downstream 
analysis, and cell pellets were discarded. 
2.5.2 Immunoprecipitation  
2 µg of respective antibody was added to approximately 300 µg of proteins from 
whole cell lysates. The antibody-lysate mix was incubated at 4 °C for 18 hours. 
Subsequently, 50 µL of Protein A (Roche 11 134 515 001) or Protein G (Roche 11 
243 233 001) agarose beads suspension were added to the antibody-lysates mix. The 
beads are incubated with the reaction mix to capture the immunocomplex for an 
additional 2 hrs at 4 °C. 
If anti-Flag M2 agarose beads (Sigma A2220) were used, 20 µL of M2 beads 
suspension are added to approximately 300 µg of proteins from whole cell lysates. 
The M2 beads-lysates is incubated at 4 °C for 2 hours under rotation to capture the 
immunocomplex. 
Subsequently, the immunoprecipitates were centrifuged and pellets were washed 
thrice, 20 minutes each in HEPES buffer. Finally, the bound proteins were eluted with 
2x Laemmli protein loading buffer) [125 mM Tris-HCl (pH 6.8), 8% SDS, 20% β-
mercaptoethanol, 40% glycerol and 0.4% bromophenol blue], boiled at 95 °C for 5 
min. The eluted proteins were then analyzed with SDS-PAGE. 
2.5.3 Analysis of proteins 
Proteins were subjected to one-dimensional sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) according to standard protocols 
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(Sambrook and Russell, 2001). Protein sample prepared according to descriptions in 
the earlier section were vortexed, boiled at 95 °C for 5 min, and centrifuged at 6000 
rpm for 1 minute at room temperature before loading into the wells of an SDS-PAGE 
gel. Molecular size reference markers are loaded in adjacent wells to facilitate 
estimation of protein molecular weights. 10% polyacrylamide gels are used generally. 
For analysis of lower molecular proteins, such as Grb2 (26kDa), 12.5% 
polyacrylamide gels are utilized. 
The electrophoresis buffer constituents are 25 mM Tris-HCl (pH 8.3), 192 mM 
glycine and 0.1% SDS. The separated proteins may be visualized using two methods: 
1) Direct staining and visualization with Coomassie Brilliant Blue Solution [0.2% 
Coomassie Brilliant Blue; 45% methanol and 10% acetic acid]. The stained gels are 
destained with 40% methanol and 10% acetic acid.  
2) Western blotting and immunodetection (see following section). 
2.5.4 Western Blotting and Immunodetection 
After electrophoretic separation, the proteins on the SDS-gel are transferred onto 
methanol pre-activated PDVF membranes at 110 V for 1 hour 10 minutes. The 
protein transfer buffer consists of 25 mM Tris-Base (pH 8.3), 192 mM glycine, 10% 
SDS and 20% methanol.  
The membrane bound proteins were incubated in blocking buffer [1% BSA in 
PBST (0.1% polyoxyethylene-sorbitan monolaurate (Tween 20) in PBS)] or [5% non-
fat milk in PBST] for 1 hr at room temperature or 18 hours at 4 oC. The blocked 
membranes were subsequently incubated with primary antibody according to 
concentrations in Table 2.1 for 1 hour (at room temperature) or 18 hours (at 4 oC). To 
remove unbound antibodies, the blots are washed three times, 15 minutes each with 
PBST or TBST. Next, the membranes were incubated with secondary antibody 
according to concentrations indicated in Table 2.2 for at least 1 hr at room 
temperature and subjected to three washes.  
I utilized two different methods for immuno-detection of proteins of interest. The 
first method is the application of Enhanced Chemi-Luminescence (ECL). Horseradish 
peroxidase (HRP) conjugated secondary antibodies recognize and bind to the primary 
antibodies bound to proteins of interest. After secondary antibody binding, the 
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membranes are incubated in ECL solution for 1 min. The HRP conjugated to the 
secondary antibodies catalyzes oxidative degradation of the chemiluminescent 
substrate resulting in light emission at a wavelength of 428 nm, which can be detected 
on an autoradiography film. The second method is facilitated by the LI-COR Odyssey 
imaging system. The system detects the fluorescent dyes conjugated to DylightTM 
secondary antibodies (Table 2.2) that are bound to proteins of interest. The 
fluorescent signals are then converted into protein bands. 
Figures 3.5, 3.14, 3.15, 3.17, 3.23, 3.47, 3.48, 4.1, 4.2, 4.5 and 5.1 were obtained 
using the ECL/X-ray film method. The rest of western blot images were obtained 
using the LI-COR Odyssey machine. 
2.5.5 Densitometry 
Western blots images (from LI-COR Odyssey) or scans (from X-ray film) are 
analyzed using Image Processing and Analysis in Java (ImageJ) software. Images 
were first processed to reduce background signal by 50.0 pixels. Thereafter, processed 
images were black-white inverted. Bands of interest were selected and measured for 
mean pixel intensity/signal. 
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2.6 Immunofluorescence microscopy 
PC12 and COS-1 cells were grown on glass cover slips coated with poly-L-lysine 
(0.01% solution, Sigma P4707), in cell culture dishes. Cells were subsequently fixed 
with 4% paraformaldehyde for 20 minutes at room temperature. Fixed cells are 
washed once with PBS, 2 times with 100 mM NH4Cl in PBS and once more again 
with PBS. Permeabilization is achieved with 0.2% Triton-X in PBS treatment for 15 
minutes. Permeabilized cells are then blocked for 1 hour with IF blocking buffer (PBS 
supplemented with 2% BSA and 5% FBS). 
Cells are probed for 1 hour at room temperature, with primary antibody 
reconstituted in IF blocking buffer. After three washes with PBS, the cells are 
incubated in dark for 1 hour with fluorophore conjugated secondary antibody 
reconstituted in IF blocking buffer. This is followed by four final washes with PBS. 
Antibodies are used in accordance to concentrations indicated above. Coverslips are 
mounted on slides with Gel/Mount (Biomeda Corp. Cat. No. MØ1) for confocal or 
fluorescence microscopy.  
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2.7 Neurite quantitation 
PC12 cell images obtained from confocal/fluorescence microscopy were 
converted to 16-bit monochromatic, gray scale, single channel images before analysis 
using the MetaMorph Microscopy Automation & Image Analysis software by 
Molecular Devices. Representative images were used to obtain optimized parameters 
for cell bodies, nuclear stain and outgrowth, found in the Neurite Outgrowth 
application on MetaMorph. 
The images in each data set were subsequently analyzed using the optimized 




Site directed mutagenesis, truncation and deletion mutagenesis were carried out 
using Polymerase Chain Reaction (PCR).  
 
General PCR setup 
Template DNA 10 ng 
10 mM each dNTP mix 1 µL 
10x Buffer mix 5 µL 
Primer mix 2 µL (20 pmol per reaction) 
Pfu Polymerase 1 µL 
Sterile H20 40 µL 
 
Cycling parameters 
Initial denature at 95 oC for 1 min 
Denature at 95 oC, 30 s 
Annealing at 55-58 oC, 1 min 
Extension at 68 oC, 13 min 
Final extension at 72 oC, 10 min 
Incubation at 16 oC, forever 
 
2.8.1 Primer design 
Primers are generally designed to be of 25 to 45 bases in length. If several 
different site-directed mutations are done in parallel, the different primer sets are 
designed to have similar melting temperatures (Tm). 
For site-directed mutagenesis, Tm = 81.5 + 0.41(%GC) – 675/N – % mismatch, 
where N is the primer length in bases.  For designing primers for deletion 
mutagenesis, Tm = 81.5 + 0.41(%GC) – 675/N, where N excludes bases to be deleted. 
Primers should have a minimum 40% GC content and terminate with one or more 
C/G bases (CG “clamp”), for more stable annealing. Both sense and antisense 
mutagenic primers must contain the desired mutation and both must recognize the 
same sequence on both strands of the plasmid. 
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When introducing a mismatch into the primer for site directed mutagenesis, it is 
preferred that the mismatch is coded by a common codon of the parent protein 
sequence. Primers for deletion mutagenesis should consist of 10-15 bases flanking 
both sides of the site of deletion. Primers for truncation mutagenesis should introduce 
a stop codon at the site of truncation. 
More information can be obtained for instructional manuals from mutagenesis kits 
such as QuikChange®.  
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2.9 Bacterial Transformation 
A mixture of 5 µL of DNA ligation products and 45 µL of competent bacterial 
cells was incubated on ice for 30 minutes, followed by one-minute heat shock at 45 
oC. Thereafter, the mixture was incubated again on ice for one minute. The bacterial 
cells were left to recover in Luria Bertani (LB) media without antibiotics (10x 
volume) at 37 oC and shaking for 30 minutes. The cells were then centrifuged at 6000 
rpm for one minute. After removing most of media, the cell pellet was re-suspended 
and plated on antibiotics selection LB Agar plates. 
The bacteria were allowed to grow at 37 oC for 16 hours. Transformed bacteria 
will be able to form colonies on the LB selection agar. Colonies are then selected for 
extraction of plasmids. 
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2.10 Xenopus methodology 
 
Figure 2.1 Representative stages of Xenopus Laevis embryos. From left to right: 
stages 2, 6, 8, 10, 13, 15, 18, 22, 25, 31 and 35 (images adapted from 
www.xenbase.org). 
 
2.10.1 Morpholino knockdown 
Morpholinos against CK1α, δ, ε, γ1 and γ2, Spry1 and Spry2 were designed and 
purchased from GeneTools, LLC. Morpholinos were dissolved in sterile H2O to give 
a final stock concentration of 8 ng/nL. The morpholinos were injected into 2-cell 
staged Xenopus Laevis embryos (refer to Figure 2.1 for phenotypic reference) at 
different concentrations: 80 ng, 40 ng or 20 ng per embryo (40 ng, 20 ng or 10 ng per 
cell). 
After injections, the embryos were allowed to develop until stage 30 (with control 
embryos as a reference) for analysis of phenotype. 
2.10.2 Xenopus Laevis animal cap assay 
Animal caps of stage 8-9 Xenopus Laevis embryos were isolated according to 
standard protocols described in “Early Development of Xenopus Laevis” (Sive, 
Grainger and Harland, 2000). 
10 isolated animal caps were pooled together, and each pool was subject to 
treatment with 20 ng/ml bFGF and/or CK1 inhibitors (50 µM D4476, 10 µM PF670, 
50 µM PF480) until embryos reach stage 10 of development (with reference to control 
embryos). The animal caps were subsequently lysed in RIPA buffer (20 mM Tris pH 
8.0, 1 mM EDTA, 0.1% NP-40, 10% glycerol and 1 mM Na3VO4, with protease 
inhibitors (Roche) and phosphatase inhibitors (Roche) added before use) for protein 
extraction. 
The animal cap assays were conducted with technical assistance from Dr. Claire 
Canning and Ms. Jessica Chan from the Mike Jones Lab, IMB. 
  
 44 
2.11 Gastric cancer database analysis 
Data from an Affymetrix expression array of 200 primary gastric cancers are 
normalized for background correction and transformed into Log2 values, previously 
by the Duke-NUS Center of Computational Biology. Subsequently the following 
probes are selected for statistical analysis: CSNK1E_222015_at, FGF1_205117_at, 
FGF4_206783_at, FGF7_205782_at and SPRY2_204011_at. 
Statistical analyses were carried out with JMP Statistical Discovery Software 
(SAS, USA). Boxplots of CSNK1E and SPRY2 values were generated against 
quartiles of FGF1, FGF4 or FGF7 values. 
Analysis of the Gastric Cancer database was conducted with assistance from Dr. 
Sujoy Ghosh, Assistant Professor in the Centre for Computational Biology, Duke-
NUS Graduate Medical School Singapore. 
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Chapter 3. CASEIN KINASE 1 REGULATES SPROUTY2 IN FGF-ERK 
SIGNALING 
This work has been accepted for publication in Oncogene, on 10th December 2013, 
and published online on 27th January 2014 (doi:10.1038/onc.2013.564). 
3.1 Abstract 
Sprouty2 (SPRY2) is a potent negative regulator of receptor tyrosine kinase 
(RTK) signaling, and is implicated as a tumor suppressor. SPRY2 inhibits FGF-RAS-
ERK signaling by binding to GRB2 during FGFR activation, disrupting the GRB2-
SOS complex that transduces signals from FGFR to RAS. SPRY2 binding to GRB2 is 
modulated by phosphorylation but the key regulatory kinase(s) are not known. Prior 
studies identified the frequent presence of CK1 phosphorylation motifs on SPRY2. I 
therefore tested if CK1 plays a role in SPRY2 phosphorylation and function. Loss of 
CK1 binding, and inhibition of CK1 activity by two structurally distinct small 
molecules abrogated SPRY2 inhibition of FGF-ERK signaling, leading to decreased 
SPRY2 interaction with GRB2. Moreover, CK1 activity and binding are necessary for 
SPRY2 inhibition of FGF-stimulated neurite outgrowth in PC12 cells. Consistent with 
its proposed role as an inhibitor of FGF signaling, find that CSNK1E transcript 
abundance negatively correlates with FGF1/FGF7 message in human gastric cancer 
samples. Modulation of CK1 activity may be therapeutically useful in the treatment of 




Receptor Tyrosine Kinase (RTK) signaling governs key cellular functions 
including proliferation and differentiation, migration, survival and metabolism 
(reviewed in (Casaletto and McClatchey, 2012; Lemmon and Schlessinger, 2010)). 
Regulatory mechanisms and feedback controls exist in the RTK pathways to ensure 
specificity in cell signaling and biological outcomes. The Sprouty (SPRY) family of 
proteins (SPRY1 through 4) are such feedback inhibitors (Casci et al., 1999; 
Impagnatiello et al., 2001; Yusoff et al., 2002). SPRY2, by modulating RTK 
pathways, controls diverse biological processes such as neurite outgrowth (Hausott et 
al., 2009; Wong et al., 2002) and tracheal branching (Hacohen et al., 1998; Metzger et 
al., 2008; Tang et al., 2011). Conversely, aberrant control of signaling by SPRY leads 
to pathological conditions. SPRY2 is downregulated in breast, liver and prostate 
cancers (Fong et al., 2006; Lo et al., 2004; Patel et al., 2013) and knockout of the 
various Spry genes causes a range of developmental disorders in mice (reviewed in 
(Edwin et al., 2009b; Guy et al., 2009)). 
SPRY2 inhibits the FGF-RAS-ERK signaling pathway. Fibroblast growth 
factor (FGF) binding to FGF receptors (FGFR) results in receptor dimerization, 
phosphorylation, and recruitment of the adaptor protein Fibroblast growth factor 
Receptor Substrate 2 (FRS2) (reviewed in (Lemmon and Schlessinger, 2010)). 
Growth factor Receptor Bound protein 2 (GRB2) subsequently transduces signals 
from FRS2 to son of sevenless (SOS). The Src-homology-2 (SH2) domain of GRB2 
docks to phosphorylated tyrosines on FRS2 while the Src homology 3 (SH3) domain 
of GRB2 recognizes proline rich sequences on SOS. Binding of GRB2 to SOS 
activates RAS by stimulating the SOS RAS-GEF (Guanine nucleotide exchange) 
activity. The activated RAS subsequently signals to the RAF-MEK-ERK MAPK 
module (reviewed in (Turner and Grose, 2010)). SPRY2 is a potent feedback inhibitor 
of FGF-RAS-ERK signaling (Casci et al., 1999; Hacohen et al., 1998; Lao et al., 
2006; Yusoff et al., 2002). Upon FGFR1 activation, a cryptic PxxPxR motif on C-
terminal SPRY2 is revealed, enabling it to bind to the SH3 domain of GRB2 (Lao et 
al., 2006). SPRY2 binding sequesters GRB2 from SOS, thus disconnecting signal 
transduction upstream of RAS (Hanafusa et al., 2002; Lao et al., 2006). 
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SPRY2 is a phosphoprotein and its phosphorylation undergoes complex 
changes during FGF signaling. While global 32P-orthophosphate incorporation into 
SPRY2 did not change significantly after growth factor stimulation (Impagnatiello et 
al., 2001), the sites of phosphorylation as assessed by mass spectrometry analysis 
changed markedly during FGFR1 activation (Lao et al., 2007). A subset of serine and 
threonine residues are phosphorylated by an unknown kinase(s), while other sites are 
dephosphorylated as a consequence of enhanced Protein Phosphatase 2A (PP2A) 
interaction with SPRY2 (Lao et al., 2007). It therefore appears that S/T kinases act in 
tandem with PP2A (or other S/T phosphatases) to unmask the PxxPxR motif, leading 
to SPRY2 binding to GRB2 and subsequent inhibition of FGF-ERK signaling. 
While several kinases have been identified that phosphorylate SPRY2 (Aranda 
et al., 2008; Chandramouli et al., 2008; DaSilva et al., 2006), little is known about 
their effect on SPRY2 function. A number of phosphorylation sites identified by both 
mass spectrometry and mutational analysis (Lao et al., 2007) conform to well-
established CK1 consensus sites of the form – pS/T-X-X-S/T (Flotow et al., 1990). 
Similar phosphorylation sites have been reported in a number of physiologic CK1 
substrates including SV40 large T antigen (Cegielska and Virshup, 1993), PER2 
(Toh, 2001), APC (Rubinfeld et al., 2001), and NFAT1 (Okamura et al., 2004). In 
SPRY2, several of the putative CK1 sites were phosphorylated in the resting, 
unstimulated state (Lao et al., 2007), consistent with constitutive interaction of 
SPRY2 with CK1. This suggested a potential role for CK1 in SPRY2 regulation.  
Here I report that endogenous CK1 isoforms interact with and regulate SPRY2 
in a phosphorylation dependent manner. Using CK1 inhibitors and various SPRY2 
mutants, I find that CK1 activity is required for SPRY2 inhibition of FGF-ERK 
signaling. Phosphorylation of SPRY2 by CK1 enables the binding of SPRY2 to 
GRB2. CK1 is physiologically relevant in the RTK-MAPK pathway, as I find that 
CK1 activity is required for SPRY2 to inhibit FGF/NGF-stimulated neurite outgrowth 
in PC12 cells. In gastric cancers with high FGF1 or FGF7, CK1ε gene (CSNK1E) 
expression is low, consistent with its proposed role as an inhibitor of the FGF-RAS-
MAPK pathway. Therapeutic CK1 inhibition may have the unintended consequence 




3.3.1 CK1 and Sprouty2 interact in a phosphorylation dependent manner 
The Serine/Threonine Rich (STR) domain of SPRY2 has several CK1 consensus 
phosphorylation motifs of the form pS/T-X-X-S/T (Figure 3.1 below).  
 
Figure 3.1. Schematic representation of SPRY2 with red-highlighted serine/threonine 
residues in the STR region. The highlighted residues form a series of CK1 consensus 
phosphorylation motifs. 
 
As several of these sites are phosphorylated in unstimulated cells, as detected by 
mass spectrometry analysis (Lao et al., 2007), I tested if SPRY2 interacts with CK1. 
SPRY2 co-immunoprecipitated with both endogenous and ectopically expressed 
CK1ε, δ and α, and this interaction was increased by co-expression of FGFR1 
(Figures 3.2, 3.3, 3.4 and 3.5 below). 
 
Figure 3.2. Flag-tagged SPRY2 was tested for interaction with endogenous CK1ε. 
The various constructs were expressed in HEK 293 cells for 16-18 hours. Cells were 
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lysed 16-18 hours after transfection of the indicated constructs, followed by 
immunoprecipitation of the indicated proteins. (* indicates IgG heavy chain. 
Henceforth WCL, whole cell lysate and numbers at the left side of blot scans indicate 
molecular weight reference markers in kilo Daltons.) 
 
 
Figure 3.3. Endogenous CK1δ immunoprecipitates (IPs) were tested for Flag-tagged 
SPRY2. The various constructs were expressed in HEK 293 cells for 16-18 hours. 
Cells were lysed 16-18 hours after transfection of the indicated constructs, followed 
by immunoprecipitation of the indicated proteins. 
 
 
Figure 3.4. Endogenous CK1α was analyzed for interaction with Flag-tagged SPRY2. 
The various constructs were expressed in HEK 293 cells for 16-18 hours. Cells were 
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lysed 16-18 hours after transfection of the indicated constructs, followed by 
immunoprecipitation of the indicated proteins. 
 
 
Figure 3.5. Flag-tagged SPRY2 and HA-tagged CK1 were overexpressed in HEK 
293 cells and Flag IPs were tested for HA-tagged CK1s.  
 
Endogenous CK1ε and δ interaction with SPRY2 increased more than 40%, while 
CK1α binding doubled with FGFR1 signaling (quantitation in Figures 3.6, 3.7 and 3.8 
below). 
 
Figure 3.6. Quantitation of CK1ε binding to SPRY2, with and without FGFR1 in 
HEK 293 cells, from three independent experiments. Band intensities were 
quantitated using ImageJ, and normalized to Flag-SPRY2 input in the whole cell 




Figure 3.7. Quantitation of CK1δ binding to SPRY2, with and without FGFR1 in 
HEK 293 cells, from three independent experiments. Band intensities were 
quantitated using ImageJ, and normalized to Flag-SPRY2 input in the whole cell 
lysates and total CK1 in the immunoprecipitates. 
 
 
Figure 3.8. Quantitation of CK1α binding to SPRY2, with and without FGFR1 in 
HEK 293 cells, from three independent experiments. Band intensities were 
quantitated using ImageJ, and normalized to Flag-SPRY2 input in the whole cell 
lysates and total CK1 in the immunoprecipitates. 
 
I next tested if CK1 phosphorylates SPRY2 in cells. It has been previously 
established that SPRY2 phosphorylation can be monitored in part by changes in 
electrophoretic mobility on SDS-PAGE (Impagnatiello et al., 2001; Lao et al., 2007). 
Co-expressed CK1 increased the SPRY2 slower migrating band (Figure 3.5 above), 
suggesting that CK1 phosphorylates SPRY2. Endogenous CK1 also appears to 
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phosphorylate SPRY2, as treatment of cells with the phosphatase inhibitor Calyculin 
A (CalA) increased SPRY2 mobility shift and abundance, and these effects of CalA 
were delayed by pre-treatment with the CK1 inhibitor PF670462 (PF670) (Figure 3.9 
below, WCL compare lanes 3 and 6). I conclude that SPRY2 binds to and is 
phosphorylated by endogenous CK1. Since PF670 is specific for CK1ε and CK1δ 
(Badura et al., 2007; Cheong et al., 2011), it appears these are the predominant 
SPRY2 kinases. 
 
Figure 3.9. Flag-tagged SPRY2 was expressed in HEK 293 cells. Cells were then 
treated with DMSO or PF670, and subsequently with Calyculin A to stimulate SPRY2 
phosphorylation. Endogenous CK1ε was immunoprecipitated and analyzed for 
interaction with Flag-tagged SPRY2. 
 
The CK1-SPRY2 interaction is phosphorylation dependent. Two independent 
inactivating mutations of CK1, D128N in CK1ε (Amit, 2002), and K38A in CK1δ 
(Lord et al., 2011), each markedly reduced the ability of CK1 to bind to SPRY2 
(Figure 3.10, 3.11 below). Correspondingly, kinase dead CK1 was unable to alter the 
electrophoretic mobility of SPRY2. 
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Figure 3.10. Kinase dead D128N CK1ε was analyzed for binding to SPRY2. Flagged 
tagged SPRY2 and HA-tagged wildtype CK1ε or kinase dead CK1ε were co-
expressed in HEK 293 cells. 
 
 
Figure 3.11. Kinase dead K38R CK1δ was tested for binding to SPRY2. Flagged 
tagged SPRY2 and Myc-tagged wildtype CK1δ or kinase dead CK1δ were co-
expressed in HEK 293 cells. 
 
Consistent with a role for phosphorylation in the CK1-SPRY2 interaction, CalA 
treatment for 15 minutes markedly increased the interaction of endogenous CK1 with 
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SPRY2 in HEK 293 cells (Figure 3.9 above). Pre-treatment with PF670 prior to CalA 
treatment prevents the increase in CK1-SPRY2 interaction (Figure 3.9, compare lanes 
3, 6 and 9). The specific phosphorylation events required for CK1-SPRY2 interaction 
have not yet been identified.  
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3.3.2 CK1 interacts with two distinct regions on Sprouty2 
I mapped the regions of SPRY2 that interact with CK1 using a series of SPRY2 
N- and C- terminal truncation mutants (Figure 3.12, 3.13, 3.14 and 3.15 below). 
 
Figure 3.12. Schematic diagram of SPRY2 truncation mutants tested for 
interaction with HA-tagged CK1ε. (+ indicates constructs that bind to HA-CK1ε.) 
 
 
Figure 3.13. Schematic diagram of SPRY2 truncation mutants tested for interaction 




Figure 3.14. SPRY2 truncation mutants binding to HA-tagged CK1ε. Flag-tagged 
wildtype SPRY2 or truncated SPRY2 mutants were co-expressed with HA-tagged 





Figure 3.15. SPRY2 truncation mutants binding to endogenous CK1ε. Flag-tagged 
wildtype SPRY2 or truncated SPRY2 mutants were expressed in HEK 293 cells for 
16-18 hrs, before immunoprecipitation of endogenous CK1ε. 
 
I observed that two domains, SPRY2 aa 211-230 and aa 179-192, each 
contributed to the binding of both overexpressed and endogenous CK1ε. Domain 1, aa 
211-230, plays a larger role in basal interaction (Figure 3.16 and 3.17). Deletion of 
both regions (SPRY2Δ179-192Δ211-230, hereafter referred to as SPRY2ΔΔ) gave 
near total abrogation of binding to the kinase both with and without FGFR1 signaling 




Figure 3.16. A SPRY2 construct lacking the first CK1ε binding site (SPRY2Δ211-
230) transiently expressed in HEK 293 cells was tested for binding to endogenous 




Figure 3.17. SPRY2 constructs lacking the second CK1ε binding region 
(SPRY2Δ179-192), and both binding regions (SPRY2Δ179-192Δ211-230, or 
SPRY2ΔΔ) were generated. Endogenous CK1ε immunoprecipitates were tested for 
Flag-tagged SPRY2 and mutant.  
 
Similar to CK1ε, CK1δ interaction with SPRY2ΔΔ was also decreased, especially 
when FGF signaling was activated (Figure 3.18, compare lanes 5 & 6).  
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Figure 3.18. Endogenous CK1δ was analyzed for interaction with Flag-tagged 
SPRY2 with and without FGFR1. HEK 293 cells were used in the above experiments. 
 
Because deletion mutants may affect overall protein folding and function, I tested 
SPRY2ΔΔ activity in CK1-unrelated assays. SPRY2 and SPRY2ΔΔ both translocated 
to membranes after bFGF stimulation (Figure 3.19) and both bound to endogenous c-
CBL (Figure 3.20), suggesting that the SPRY2ΔΔ mutation did not hinder global 
SPRY2 activity. I therefore used SPRY2ΔΔ as a loss-of-CK1-binding SPRY2 mutant 
for further studies. 
 
Figure 3.19. Flag-tagged SPRY2ΔΔ was tested for membrane translocation in COS-1 
cells, stimulated by bFGF or NGF. Cortactin was used as a membrane marker. 
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Figure 3.20. The interaction of endogenous c-CBL and ectopically expressed Flag-
tagged wildtype and mutant SPRY2, as indicated, were analyzed by 
immunoprecipitation and immunoblotting. FGFR1 and the CK1 inhibitor PF670 were 
added where indicated. Disheveled 2 (DVL-2) band shift was used as a readout for 
PF670 activity (Cheong et al., 2011). Flag-SPRY2Δ50-60 was reported to be a non-





3.3.3 CK1 is required for Sprouty2 inhibition of FGF-ERK signaling 
SPRY2 is an antagonist of FGF-stimulated ERK activation. I asked if CK1 
regulates this function of SPRY2. In control experiments, phosphorylated ERK 
peaked around 7 minutes following FGF stimulation of HEK 293 cells, and as 
expected, the peak signal is decreased in SPRY2 transfected cells (Figure 3.21).  
 
Figure 3.21. Time course of ERK activation after bFGF stimulation in the absence or 
presence of ectopic SPRY2, analyzed by SDS-PAGE and immunoblotting. HEK 293 
cells were transiently transfected with empty vector or Flag-tagged SPRY2. 16-18 hrs 
after transfection, cells were serum starved for 2 hrs and subsequently stimulated with 
growth factor for the indicated durations. (EV, empty vector.)  
 
To test if CK1 kinase activity regulates SPRY2 inhibition of FGF-ERK signal, I 
inhibited CK1 activity by pre-treating cells with PF670 for 1 hour prior to FGF 
stimulation. CK1 inhibition renders SPRY2 ineffective in inhibiting the FGF-ERK 
signal from 5-10 minutes post stimulation (Figure 3.22, 3.23). 
 
Figure 3.22. HEK 293 cells were transfected with 5 ng Flag-tagged ERK2, and 10 ng 
Flag-SPRY2 expression plasmids or empty vector as indicated. CK1 inhibition with 1 
 62 
µM PF670 for 1 hr, before serum starvation of 2 hrs and 6 min growth factor 
stimulation, abrogates the effect of SPRY2 in inhibiting bFGF-ERK signaling at 7 
minutes post-stimulation. Asterisks indicate T-tests for significance (*, p = 0.035, **, 
p = 0.01, n.s., not significant). Quantitation obtained from three independent 
experiments. 
 
Figure 3.23. PF670 prevents SPRY2 inhibition of bFGF-ERK signaling. HEK 293 
cells were transiently transfected with Flag-tagged SPRY2. 16-18 hrs after 
transfection, cells were serum starved for 2 hrs and subsequently stimulated with 
growth factor for the indicated durations.  
 
To confirm that this effect is due to inhibition of CK1 rather than an off-target 
effect of PF670, I tested a structurally unrelated CK1 inhibitor, D4476 (Rena et al., 
2004). D4476 treatment similarly reverses the inhibitory effect of SPRY2 on bFGF-
induced ERK activation (Figure 3.24).  
 
Figure 3.24. D4476 abrogates SPRY2 inhibition of bFGF-ERK signaling at 7 minutes 
post-stimulation. Asterisks indicate T-tests for significance (*, p = 0.032, **, p = 
0.033). Quantitation obtained from three independent experiments. 
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Therefore, CK1 kinase activity is necessary for the inhibitory capacity of SPRY2 
in FGF-ERK signaling. To test if CK1 interaction with SPRY2 is important for 
SPRY2 function, I compared the inhibitor effect of wildtype versus SPRY2ΔΔ on 
ERK activation. SPRY2ΔΔ, while expressed at higher amounts than WT SPRY2, was 
unable to inhibit FGF-ERK signal (Figure 3.25).  
 
Figure 3.25. Flag-tagged SPRY2ΔΔ is less effective than wild-type Flag-SPRY2 in 
suppression of bFGF-stimulated ERK signaling. 
 
CK1 inhibition by PF670 in the absence of transfected SPRY2 also gave increased 
FGF-ERK signal (Figure 3.22 above, compare lanes 1 and 3). Taken together, the data 




3.3.4 CK1 is required for Sprouty2-GRB2 interaction 
At least two necessary steps have been identified for SPRY2 to inhibit FGF-ERK 
signaling. First, SPRY2 must translocate to the plasma membrane upon activation of 
growth factor signaling (Casci et al., 1999; Lim et al., 2002). Second, SPRY2 must 
bind to GRB2 (Hanafusa et al., 2002; Lao et al., 2006). In FGFR1 signaling, SPRY2 
competes with SOS for binding to GRB2, sequestering GRB2 from SOS, thus 
disrupting the signaling pathway upstream of RAS and RAF (Hanafusa et al., 2002; 
Lao et al., 2006). I therefore tested the role of CK1 in each of these steps. 
FGF mediated SPRY2 translocation to the membrane upon was previously 
reported in COS cells (Hanafusa et al., 2002; Lim et al., 2000). I find that FGF-
stimulated recruiting of SPRY2 to the plasma membrane was not blocked by deletion 
of CK1 binding sites on SPRY2 (using SPRY2ΔΔ) (Figure 3.19 above). I next asked 
if CK1 activity is required for SPRY2-GRB2 interaction in the presence of FGFR1 
signaling. I examined the SPRY2-GRB2 interaction in the presence of the CK1 
inhibitors PF670 and D4476. Treatment with either of these CK1 inhibitors for 2 
hours prior to cell lysis abrogated SPRY2 binding to endogenous GRB2 (Figure 3.26, 
3.27). 
 
Figure 3.26. HEK 293 cells expressing FGFR1 and Flag-tagged SPRY2 were treated 
with DMS or PF670 as indicated. Flag-IPs were tested for endogenous GRB2.  
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Figure 3.27. HEK 293 cells expressing FGFR1 and Flag-tagged SPRY2 were treated 
with DMSO or D4476 as indicated. Flag-IPs were tested for endogenous GRB2.  
 
 CK1 binding to SPRY2 is also necessary for SPRY2-GRB2 interaction. 
SPRY2ΔΔ is unable to interact with endogenous GRB2 as efficiently as wildtype 
SPRY2 (Figure 3.28). I conclude that CK1 activity and recruitment is important for 
SPRY2 to interact with GRB2. 
 
Figure 3.28. Flag-tagged SPRY2ΔΔ was tested for interaction with endogenous 
GRB2 in HEK 293 cells. 
 
In addition to binding to GRB2, SPRY2 has also been reported to interact with the 
E3 ubiquitin ligase c-CBL, although the physiological role(s) of the SPRY2-c-CBL 
interaction is unclear since the inhibitory function of SPRY2 on FGF-ERK signaling 
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is independent of the SPRY2-c-CBL interaction (Guy et al., 2009; Lao et al., 2006). 
Nonetheless, I asked if CK1 facilitates the SPRY2-c-CBL interaction. I find that 
neither inhibition of CK1 activity by PF670, nor deletion of CK1 binding on SPRY2 
(SPRY2ΔΔ) abrogates FGFR1 mediated c-CBL-SPRY2 binding (Figure 3.20). While 
CK1 regulates SPRY2-GRB2 interaction as well as SPRY2 inhibition of FGF-ERK 
signaling, it does not influence the SPRY2-c-CBL interaction. 
Other serine/threonine kinases have been found to interact with the C-terminus of 
SPRY2. DYRK1A interacts with SPRY2 aa 164-255 (Aranda et al., 2008). Tesk1 
binds to SPRY2 C-terminus (aa 179-315) (Chandramouli et al., 2008). Both 
DYRK1A and TESK1 may be negative regulators of SPRY2 inhibition of FGF-ERK 
signaling. Therefore using the SPRY2ΔΔ mutant, I tested if DYRK1A and TESK1 
shared the same binding regions as CK1 on SPRY2. I observe that the deletion of 
CK1 binding sites (SPRY2ΔΔ) does not abrogate interaction with TESK1 (Figure 
3.29, lane 9). The TESK1 binding region on SPRY2 is therefore likely to be distinct 
from that of CK1. However, binding to DYRK1A is diminished in SPRY2ΔΔ (Figure 
3.29, lane 7). I speculate that CK1 and DYRK1A compete for binding to SPRY2, and 
the CK1/DYRK1A association with SPRY2 may vary in different cellular contexts. 
 
Figure 3.29. Flag-tagged SPRY2ΔΔ IPs were tested for interaction with HA-tagged 
DYRK1A and Myc-tagged TESK1. HEK 293 cells were used in (B) and (C). (* 
indicates non-specific band.  
 67 
3.3.5 CK1 regulates Sprouty2 inhibition of FGF/NGF neurite outgrowth 
Besides inhibiting FGF signaling to ERK, SPRY2 also blocks FGF and NGF 
mediated processes in neuronal cells (Gross et al., 2007; Hausott et al., 2009; Wong et 
al., 2002). SPRY2 prevents neurite outgrowth induced by FGF and NGF (Figures 
3.30 and 3.32, third column from left). Therefore, I tested if CK1 regulates SPRY2 
inhibition of FGF- or NGF-induced neurite outgrowth. Pre-treatment of PC12 cells 
with CK1 inhibitors PF670 or D4476 prior to FGF or NGF stimulation rescued 
SPRY2 inhibition of neurite outgrowth (Figure 3.30 and 3.32). Binding of CK1 to 
SPRY2 is essential for its function, as SPRY2ΔΔ expression fails to inhibit neurite 
outgrowth (Figure 3.30 and 3.32). Additional PC12 cell images are in Figures 3.36, 
3.37 and 3.38. 
Inhibition of CK1 either by blocking its kinase activity or by deleting its binding 
site on SPRY2 restored the mean number of FGF- or NGF- stimulated neurite 
processes towards that are seen in the absence of SPRY2 (Figure 3.31 and 3.33). 
These cell-based results are consistent with the biochemical evidence that the 
inhibitory effect of SPRY2 requires CK1. In addition, it demonstrates that CK1 
activation of SPRY2 function can be seen in more than one cell line. 
I noted too, that PF670 or D4476 treatment of unstimulated PC12 cells induced 
neurite outgrowth in PC12 cells (Figure 3.34), with an approximately six-fold 
increase in the mean number of neurite processes (Figure 3.35). This is consistent 
with the published observation that CK1ε knockdown promotes neurite outgrowth in 
unstimulated TC-32 cells (Greer and Rubin, 2011). Taken together, I propose that 




Figure 3.30. MetaMorph quantitation of bFGF induced neurite outgrowth with 
representative images of cells. Cells were transfected with Flag-tagged wildtype or 
SPRY2ΔΔ expression vectors. PF670 was used at 1 µM, and D4476 was used at 10 




Figure 3.31. Mean number of neurite processes in PC12 cells transfected with various 
SPRY2 constructs under the indicated conditions. Error bars indicate the 95% 





Figure 3.32. MetaMorph quantitation of NGF induced neurite outgrowth with 
representative images of cells. Cells were transfected with wildtype SPRY2 or Flag-




Figure 3.33. Mean number of neurite processes in PC12 cells transfected with various 
SPRY2 constructs, subjected to the indicated conditions. Error bars indicate 95% 





Figure 3.34. MetaMorph quantitation of neurite outgrowth of PC12 cells in the 




Figure 3.35. Mean number of neurite outgrowths in PC12 cells with and without CK1 




Figure 3.36. Representative images of PC12 cells. Cells were transfected with either 
empty vector plasmids or Flag-SPRY2. Subsequently, cells were pre-treated with 





Figure 3.37. Representative images of PC12 cells. Cells were transfected with either 
empty vector plasmids or Flag-SPRY2. Subsequently, cells were pre-treated with 





Figure 3.38. Representative images of PC12 cells. Cells were transfected with either 
empty vector plasmids, Flag-SPRY2 or Flag-SPRY2. Subsequently, cells were 




3.3.6 CK1-Sprouty2 in gastric cancers 
Increased autocrine and paracrine signaling by growth factors such as FGFs 
contribute to oncogenic signaling (reviewed in (Turner and Grose, 2010)). 
Amplification of FGF1 has been reported in ovarian cancers (Birrer et al., 2007; 
Smith et al., 2012), with paracrine FGF1 facilitating angiogenesis (Birrer et al., 2007). 
In gastric cancers, FGF7 (or Keratinocyte Growth Factor (KGF)) protein and 
transcript has been found upregulated in fibroblasts (Nakazawa et al., 2003), 
contributing to cancer cell proliferation in a paracrine manner. FGF1 and FGF7 
negatively correlate with patient survival in gastric cancer (Toyokawa et al., 2009) 
and FGF1 expression may cause a poor response to cisplatin in ovarian cancer (Smith 
et al., 2012). Given the potential roles of FGF signaling in gastric cancers, as well as 
the function of SPRY2 in the signaling pathway, I asked if there is a correlation 
between SPRY2, CK1 and FGF gene expression in gastric cancers. 
Analysis of gene expression data from 200 primary gastric cancers (a dataset 
previously described in (Lei et al., 2013; Ooi et al., 2009)) revealed that SPRY2 
transcript levels do not correlate with levels of FGF1, FGF7 (Figure 3.39 and 3.40) or 
FGF4 (Figure 3.41). Instead, I found that CSNK1E expression negatively correlated 
with that of FGF1 and FGF7 (Figure 3.39 and 3.40).  Similar results were obtained 
with a separate CSNK1E probe (Figure 3.42). This correlation appears to be specific 
to a subset of FGFs, as CSNK1E expression did not vary with FGF4 expression 
(Figure 3.41). After correction for multiple testing, I find a significant decrease in 
CSNK1E but not in CSNK1A1 or CSNK1D expression as FGF1 and FGF7 expression 




Figure 3.39. CSNK1E negatively correlates with FGF1 transcripts in human gastric 
cancers. Log2 values of the indicated gene expression are plotted against FGF 
expression quartiles (Q1 being the lowest value, and Q4 the highest). P-values of 




Figure 3.40. CSNK1E negatively correlates with FGF7 transcripts in human gastric 
cancers. Log2 values of the indicated gene expression are plotted against FGF 
expression quartiles (Q1 being the lowest value, and Q4 the highest). P-values of 





Figure 3.41. CSNK1E and SPRY2 boxplots against FGF4 quartiles. 
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Figure 3.42. A second CSNK1E probe was tested for correlation with FGF1, 4 and 7 









Figure 3.44. CSNK1D boxplots against (from top to bottom) FGF1, FGF4 and FGF7 
quartiles. 
 
Although CK1ε, δ and α may regulate SPRY2 and FGF signaling in cell-based 
assays, CK1ε gene downregulation in gastric cancers with increased FGF1 and 7 
expressions is unique among the CK1 family, suggesting tissue specific roles of CK1 
isoforms in FGF signaling.   
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3.4 Discussion 
Here I demonstrate that CK1 is a key regulator of SPRY2 function in RTK 
signaling. CK1 binds to SPRY2 in a phosphorylation-dependent manner, and 
phosphorylation by CK1 makes SPRY2 a more potent inhibitor of RTK signaling. 
SPRY2 binding to GRB2 is regulated by CK1 activity. This interaction is biologically 
relevant, as CK1 inhibition counteracts SPRY2 inhibition of FGF and NGF-
stimulated neurite outgrowth. The downregulation of CK1ε gene expression in FGF1 
and FGF7-high gastric cancers suggests this mechanism functions in cancer 
proliferation. These findings also suggest that pharmacologic inhibition of CK1 may 
increase the intensity and duration of growth factor signaling in vivo. 
The phospho-regulation of SPRY2 function is complex (Impagnatiello et al., 
2001; Lao et al., 2007). Other SPRY2-associated S/T kinases (DYRK1A and TESK1) 
have been previously identified. However, their activity is reported to inactivate, 
rather than activate, SPRY2 function (Aranda et al., 2008; Chandramouli et al., 2008). 
The data suggest there are SPRY2 activating sites that are phosphorylated by CK1, 
while inactivating sites are phosphorylated by DYRK1A and TESK1. The 
phosphorylation of both sets of sites is increased by phosphatase inhibitors and by 
mutants of SPRY2 that cannot bind to PP2A. Here I show that decreasing the S/T 
phosphorylation of SPRY2 by CK1 inhibition, through either PF670/D4476 or 
mutation of CK1 binding sites, is also sufficient to decrease SPRY2-GRB2 
interactions (Figures 3.26, 3.27 and 3.28). CK1 activity and binding is likewise 
necessary for the capacity of SPRY2 to inhibit FGF-ERK signaling (Figures 3.21 to 
3.25) and FGF/NGF mediated neurite outgrowths (Figures 3.30 to 3.38). Since both 
CK1 and PP2A activate SPRY2, I suggest that CK1 is a kinase that functions in 
parallel with PP2A to achieve fine balance of the post-translational modification on 
activated SPRY2 (Figure 3.45). 
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Figure 3.45. Model of SPRY2 activation in the FGF-ERK pathway. Resting state 
SPRY2 adopts a conformation with its PxxPxR domain inaccessible for GRB2 
binding. During FGF signaling, phosphorylation changes on SPRY2 due to both S/T 
kinases and phosphatases, such as CK1 and PP2A, facilitate the unmasking of the 
GRB2 interaction motif. This leads to SPRY2 sequestration of GRB2, and inhibition 
of FGF signaling to ERK. 
 
CK1 has been implicated in diverse cellular processes including the Wnt/β-catenin 
pathway, Hedgehog signaling, p53 tumor suppression, and circadian rhythms 
(reviewed in (Cheong and Virshup, 2011)). This report places CK1 in the FGF-ERK 
pathway. Centrosome-localized CK1δ is required for Wnt3a-stimulated neurite 
outgrowth in Ewing Sarcoma-derived cell lines (Greer and Rubin, 2011) in a 
mechanism that requires DVL phosphorylation. Conversely, they found that 
knockdown of CK1ε induced neurite outgrowths in unstimulated cells, in agreement 
with my finding that the CK1 inhibitor PF670 stimulated neurite outgrowth in PC12 
cells (Figure 3.34 and 3.35). Thus, not surprisingly, CK1 has diverse roles in cells and 
these activities are determined in part by the localization and interaction partners.  
The implication of CK1 and PP2A in modulating FGF and NGF signaling also 
suggests a possible mechanism of cross-talk with other pathways. CK1ε was found to 
be activated by Wnt (Swiatek et al., 2004) and glutaminergic signals (Liu et al., 
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2002b). PP2A likewise may be activated by pathways such as β2 adrenergic signaling 
(Pullar et al., 2003). In activating CK1 or PP2A, these signaling pathways may 
modulate downstream growth factor signaling. 
Among the SPRY family of proteins, the C-terminal PxxPxR GRB2 binding motif 
is found solely in SPRY2. This unique characteristic of SPRY2 could explain why it 
inhibits FGF-ERK signaling, while SPRY1 and 4 have negligible effects on the 
pathway (Lao et al., 2006). Homologous regions of the CK1 binding regions on 
SPRY2, aa 179-192 and 211-230, are found in other SPRY family members (Figure 
3.46, yellow and bold highlights). In addition, consensus CK1 phosphorylation sites 
are found also in the S/T rich domains of the other SPRY family members (Figure 
3.46, green highlight). I observed that SPRY1 and 4 interacts with CK1ε and CK1δ, 
and SPRY4 but not SPRY1 binds to CK1α (Figures 3.47 and 3.48). Interestingly, 
although CK1α binding to SPRY1 is negligible, co-expression of the kinase induces 
mobility shifts in SPRY1 (Figure 3.47, lane 2). CK1 expression however did not 
induce significant changes in SPRY4 electrophoretic mobility (Figure 3.48). 
Therefore, CK1 may regulate the functions of other SPRY family members, but 
through different downstream mechanisms.  
 
Figure 3.46. Sequence conservation in the human SPRY family. Multiple sequence 
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alignment was generated with ClustalX. CK1ε binding sites on SPRY2 and the 
corresponding sequences in the other family members are indicated with yellow 
highlights. Conserved residues are indicated in bold font. Green highlights the STR 
domain on SPRY2 and the corresponding sequences in the other family members. 
 
 
Figure 3.47. Flagged tagged SPRY1 was tested for interaction with HA-tagged 
CK1α, δ and ε in HEK 293 cells. 
 
 
Figure 3.48. Flagged tagged SPRY4 was tested for interaction with HA-tagged 
CK1α, δ and ε in HEK 293 cells. 
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Given the robust biochemical phenotypes seen in CK1 regulated SPRY2 function 
in FGF-ERK signaling and FGF/NGF mediated PC12 neurite outgrowth assays, 
modulation of SPRY2 function through CK1 may assist in treating FGF related non-
malignant diseases. The FGF signaling cascade has an in-built negative feedback 
mechanism through SPRY2. Therefore, the use of FGF for therapies may be 
biologically useful but clinically limited. We see this in the example of TAMARIS, a 
phase 3 FGF-gene therapy trial for critical limb ischemia (Belch et al., 2011). 
Although TAMARIS failed in phase 3 studies with no significant reduction of deaths 
or the need for limb amputations, the therapy is still promising with no known safety 
problems. If SPRY2 feedback contributes to the failure of this therapy, CK1 
inhibition may provide a solution in part to the FGF feedback loop, and may increase 
the efficacy of FGF therapies. In fact, many FGFs and FGFRs have other existing or 
proposed clinical uses in treatment of Parkinson’s disease, wound healing, hair 
growth, diabetes and several types of cancers (reviewed in (Beenken and 
Mohammadi, 2009)). CK1 inhibition may be useful for combinatorial therapies with 
FGFs or FGFRs. However, inhibiting CK1 in FGF/FGFR driven cancers may have 
the undesired effect of increased ERK activity.  
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Chapter 4. UNPUBLISHED WORK 
4.1 Introduction 
4.1.1 CK1 binding motifs 
CK1 substrates such as Period, NFAT, Axin and Disheveled contain I-X-X-X-I or 
F-X-X-X-F motifs that are necessary for biochemical interaction with CK1 (Okamura 
et al., 2004). I examined the protein sequence of Spry2 (Figure 1.5) and found that 
Spry2 is devoid of these motifs. Since CK1 interacts with Spry2, the absence of the I-
X-X-X-I or F-X-X-X-F motifs on Spry2 raises the question of the existence of other 
sequence motifs that facilitate interaction with CK1.  
4.1.2 CK1-Sprouty2 in Xenopus developmental biology 
In Xenopus Laevis, Spry2 regulates gastrulation movements by inhibiting FGF 
signaling (Nutt et al., 2001). However Spry2 appears to inhibit FGFR activated 
morphogenesis in Xenopus Tropicalis through an MAPK independent pathway, 
instead working to modulate the FGF-Ca2+/PLCγ pathway (Sivak et al., 2005). Hence 
it is apparent that the functions of Spry2 in early developmental processes are context 
dependent. Nonetheless, I asked the question whether CK1 regulates Spry2 in 
developmental processes. Do the biochemical phenotypes observed from cell culture 
studies relate to developmental biology of an organism? 
4.1.3 GSK3-CK1-Sprouty2 
GSK3 is another major cellular S/T kinase that is involved in many intracellular 
signaling pathways such as Wnt and Hedgehog signaling, the circadian clock and the 
PI3K-AKT-mTOR pathway. The importance of GSK3 function is highlighted by the 
fact that deregulated GSK3 is often associated with a variety of diseases like Type 2 
Diabetes and bipolar disorders. GSK3 and CK1 are closely related kinases in biology, 
both share close mechanistic relationships in signaling transduction (elaborated in the 
paragraph below), and also are both found implicated in the same neurodegenerative 
disorders, such as Alzheimer’s disease and Parkinson’s disease.  
Besides CK1, the Spry2 protein sequence contains phosphorylation sites for other 
S/T kinases, such as GSK3 and CK2 (Table 1.1). It is interesting that some CK1 
consensus phosphorylation sites on Spry2 are found upstream to that of GSK3 (S/T-
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X-X-X-pS/T). GSK3 shows preference for phospho-sites that lay 4 residues 
downstream of a “primed” site – a pre-phosphorylated residue. This observation led 
us to ask if CK1 acts as a priming kinase for GSK3, and if GSK3 interacts with Spry2. 
This CK1-GSK cooperation is found in β-catenin phosphorylation: CK1α “primes” β-
catenin on serine 45 for downstream phosphorylation by GSK3 on threonine 41, 
serine 37 and serine 33 (Amit, 2002; Liu et al., 2002a; Yanagawa et al., 2002). This 
sequence of phosphorylation events by the two kinases is crucial for Wnt/β-catenin 
signaling. Therefore I ask if GSK3 also plays a role in Spry2 phosphorylation and 
function, and if CK1 is necessary for the possible GSK3-Spry2 functional interaction.  
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4.2 Results 
4.2.1 Searching for possible CK1 binding motifs 
In chapter three, I reported that residues 211-230 and 179-192 on Spry2 are 
necessary regions for endogenous CK1ε binding. Point alanine mutants were 
generated using site directed mutagenesis against every residue in these two regions. 
Point mutants against aa 179-192 were generated using Spry2Δ211-230 as vector 
backbone and binding of the mutants to CK1ε in the presence of FGFR1, in 
consideration that deletion of residues 211-230 on Spry2 is insufficient to reduce 
CK1ε binding significantly in the context of FGFR1 signaling. 
Immunoprecipitating CK1ε and looking for interaction of the kinase with the 
point mutants in HEK 293 cells indicated that while none of the point mutants were 
sufficient to abrogate CK1ε binding, some of the mutants actually increased binding 
to the kinase (Figures 4.1 and 4.2). In fact, a sequential increase in binding is 
observed every 3-5 residues. 
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Figure 4.1 in 2 parts. Site directed mutagenesis of Spry2 aa 211-230. Point mutants 




Figure 4.2 in 2 parts. Site directed mutagenesis of Spry2 aa 179-192 in the context of 
Spry2Δ211-230. Point mutants are tested for interaction with endogenous CK1ε. 
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While no new CK1 binding motifs can be inferred from the data, it is likely that 
Spry2-CK1 interaction is dependent on protein tertiary structure. To better understand 
the nature of Spry2 interaction with CK1, other methods (perhaps biophysical 
techniques or protein crystallography) may need to be used. 
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4.2.2 CK1-Sprouty2 in Xenopus Laevis development 
I injected morpholinos of Spry2 and isoforms of CK1 into 2 cell-staged Xenopus 
Laevis embryos and observed for phenotypic changes. The Niehrs lab previously 
reported that moCK1γ resulted in embryos with defective tail and head phenotypes, 
augmented heads and cement glands (Davidson et al., 2005). Spry2 morpholino 
knockdown embryos gave phenotypes that closely resemble that of CK1γ (Figure 
4.3), displaying shortened body axes and kinked-tail phenotypes. 
Morpholino knockdown of CK1α and ε (40 ng per embryo) gave more severe and 
varied developmental defects, ranging from shortened body axes to under-developed 
head structures. CK1δ does not seem to play a crucial role in Xenopus embryo 
development, with 80 ng per embryo injections giving little phenotypic changes. 
Whether the differences in observed phenotypes are the result of distinct underlying 











Figure 4.3 Morpholino knockdown of Spry2 and CK1 isoforms in Xenopus Laevis. 
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The Xenopus animal cap is the region that forms the blastula of an early gastrula 
stage embryo (about stage 8-9). Since FGF induces signaling to ERK in animal caps, I 
asked the question if inhibition of CK1 could modulate this signal. I treated animal 
caps with DMSO or CK1 inhibitors (D4476, PF670 or PF480) and assayed for 
phosphorylated ERK. I find that CK1 inhibition is able to potentiate FGF-ERK 
signaling in these animal caps (Figure 4.4). 
 
Figure 4.4 Inhibition of CK1 kinase activity potentiates FGF-ERK signaling in 
Xenopus Laevis animal caps. 
 
 This observation raises several questions, since the Amaya lab reported that 
Spry2 does not inhibit the FGF-MAPK in animal caps (Nutt et al., 2001; Sivak et al., 
2005). Firstly, is CK1 modulation of this pathway independent of Spry2? Secondly, if 
so what is the underlying molecular mechanism for CK1 action? Thirdly, is xSpry2 
expressed in animal caps? Could CK1 inhibition be working though Spry2 to give the 
observed potentiation of FGF-ERK signal? 
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4.2.3 CK1ε facilitates GSK3β-Sprouty2 interaction 
I co-expressed HA-tagged GSK3β, HA-tagged CK1ε, and Flag-tagged Spry2 in 
HEK 293 cells, and looked for the presence of either kinase in Spry2-Flag 
immunoprecipitates. CK1ε interacts with Spry2 constitutively, as I consistently 
observed regardless of presence of FGFR1 (Figure 4.5, lanes 5 and 12). Co-
expression of GSK3β with Spry2 did not give a Spry2 band mobility shift as observed 
with CK1ε (Figure 4.5, comparing lane 5 and 6; 12 and 13). The absence of Spry2 
band shift corresponds to the absence of GSK3β interacting with Spry2; since GSK3β 
does not bind Spry2 it is unable to phosphorylate Spry2 as well. 
 
Figure 4.5 GSK3β requires CK1ε for binding to Spry2. 
 
When GSK3β is co-expressed with both CK1ε and Spry2 (Figure 4.5 lanes 7 and 
14), GSK3β is detected in Spry2-Flag immunoprecipitates. It is interesting that 
GSK3β is found interacting with Spry2 only when CK1ε is present, suggesting that 
GSK3β-Spry2 interaction with facilitated by CK1ε. It is also possible that GSK3β, 
CK1ε and Spry2 exist in a complex. 
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However, since both kinases are expressed at supra-physiological levels additional 
experiments need to be carried out to verify this observation and the hypothesis of a 
functional GSK3β–CK1ε–Spry2 complex. For instances, siRNA knockdown studies 
of endogenous kinases (CK1 and GSK) may be conducted. The utility of siRNA for 
CK1-Spry2 studies will be discussed more in the next section. 
  
 96 
4.2.4 Possible redundancies of CK1 isoforms in regulating Spry2 
CK1α, δ and ε all bind Spry2 (Figure 3.5), and to test which CK1 isoform may be 
have predominant role in Spry2 function, I knocked down individual isoforms using 
small interfering RNA (siRNA). I used two different siRNAs targeting distinct 
sequences on CK1ε and CK1δ mRNA, and one siRNA against CK1α. 
I found that knockdown of CK1ε alone using two independent siRNAs, #11 and 
#12, did not result in the loss of Spry2 function. Spry2 still inhibits FGF-ERK 
signaling despite loss of CK1ε (Figure 4.6).   
 
Figure 4.6 HEK 293 cells were transfected with indicated siRNA for 4-5 hrs and left 
to incubate for 2 days. Empty vector or Flag-tagged Spry2 were then transfected into 
the cells as indicated and left to express for 16-18 hrs. Cells were then serum starved 
for 2 hrs before stimulation with 5 ng/ml bFGF. Cells were then lysed and protein 
lysates analyzed for the indicated proteins. 
 
Knockdown of CK1δ alone using two siRNAs, #18 and #20 (Figure 4.7), as well 
as knockdown of CK1α alone with siRNA #13 (Figure 4.8) gave the same result as 




Figure 4.7 HEK 293 cells were transfected with indicated siRNA for 4-5 hrs and left 
to incubate for 2 days. Empty vector or Flag-tagged Spry2 were then transfected into 
the cells as indicated and left to express for 16-18 hrs. Cells were then serum starved 
for 2 hrs before stimulation with 5 ng/ml bFGF. Cells were then lysed and protein 
lysates analyzed for the indicated proteins. 
 
 
Figure 4.8 HEK 293 cells were transfected with indicated siRNA for 4-5 hrs and left 
to incubate for 2 days. Empty vector or Flag-tagged Spry2 were then transfected into 
the cells as indicated and left to express for 16-18 hrs. Cells were then serum starved 
for 2 hrs before stimulation with 5 ng/ml bFGF. Cells were then lysed and protein 
lysates analyzed for the indicated proteins. 
 
The redundancy of the CK1 isoforms tested in the above cell-culture based assay 
seems to conflict with the Xenopus morpholino knockdown phenotypes observed in 
figure 4.3. However, the development of the whole organism requires more than just 
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FGF-ERK signaling. Although CK1 isoforms may have redundant roles in regulating 
Spry2 in FGF-ERK signaling, they may have distinct roles in development of the 
embryo, and whether these roles involve Spry2 is not known. 
I also tested the effects of CK1 siRNA knockdown on Spry2 binding to Grb2. 
 
Figure 4.9 HEK 293 cells were transfected with indicated siRNA (*100 nM total per 
sample) for 4-5 hrs and left to incubate for 2 days. Flag-tagged Spry2, FGFR1 and 
ERK2 were then transfected into the cells as indicated and left to express for 16-18 
hrs. Cells were then lysed, Flag-tagged Spry2 immunoprecipitated and tested for 
Grb2. 
 
Knockdown of CK1ε protein by #11 was efficient, but did not affect Spry2-Grb2 
interaction (Figure 4.8, lane 3). Although siCK1ε #12 gave reduction in Spry2-Grb2 
binding (Figure 4.8, lane 4), the knockdown of CK1ε was not efficient. It is possible 
that the reduction of Spry2-CK1 binding by siCK1ε #12 is due to lower expression of 
FGFR1 in this particular experiment (lane 4). CK1δ knockdown by #18 or #20 gave 
efficient decrease in CK1δ protein expression and inhibited Spry2-Grb2 interaction 
(Figure 4.8, lanes 5 and 6). CK1δ may be more important than CK1ε in regulating 
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Spry2-Grb2 interaction. Double CK1ε/CK1δ knockdown also gave efficient reduction 
in Spry2-Grb2 binding (Figure 4.8 lanes 7 and 8). 
Why did CK1δ regulate Spry2-Grb2 interaction, but knockdown of CK1δ did not 
result in loss of Spry2 inhibition of FGF-ERK signaling? It may be that siCK1δ 
knockdown was incomplete in the experiment shown in figure 4.6. Furthermore I 
overexpressed FGFR1 in the experiment shown in figure 4.8. Therefore these 
differences may be due to specific signaling by the over-expressed FGFR1, in contrast 
with the experiment presented in figure 4.6 where multiple endogenous FGF receptor 
isoforms (for example FGFR1-4) may be signaling. 
Since kinase dead CK1 failed to bind Spry2 (Figure 3.10 and 3.11), I also looked 
at whether CK1 inhibition blocks CK1ε-Spry2 binding. Inhibition of CK1 by both 
PF670 and D4476 decreased CK1-Spry2 by approximately 25% (Figure 4.9), unlike 
the near total loss of Spry2 binding with kinase dead CK1 (Figure 3.10 and 3.11).  
 
Figure 4.10 Empty vector or Flag-tagged Spry2 were transfected into HEK 293 cells 
as indicated and left to express for 16-18 hrs. Cells were treated with PF670 and 
D4476 at the indicated concentration for 2 hrs. Cells were then lysed and endogenous 
CK1ε immunoprecipitated and tested for Flag-tagged Spry2. Dvl2 bandshift was used 
as a functionality test for CK1 inhibitors. Protein bands were quantified using ImageJ. 
 
The possible reasons for the weaker effect of CK1 inhibition include: 1) There 
may be a long-lived CK1 phosphorylation site on Spry2 that controls Spry2 binding to 
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the kinase. 2) PF670 and D4476 may not be inhibiting all isoforms of CK1. There is 
no report that either or both compounds inhibit CK1γ or CK1α. 3) There may be 
another kinases regulating Spry2-CK1 binding and function. There are multiple 
consensus phosphorylation sites for other kinases such as GSK3 and CK1 on the S/T 
rich domain of Spry2 (Figure 3.1 and table 1.1).  
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Chapter 5. FUTURE DIRECTIONS 
5.1 Pharmacological manipulation of Sprouty2 activity 
The discovery that CK1 regulates Spry2 function opens the possibility of 
modulating Spry2 activity with small chemical compounds. Edwin et al. commented 
that small molecule modulation of Spry activity is absent despite being implicated a 
variety of diseases (Edwin et al., 2009b). They went on predict the development of 
drugs targeting Spry2 function as therapeutics against Spry2 related pathological 
conditions.  
This work is the first instance of pharmacological manipulation of Spry2 activity. 
Treatment with PF670 and D4476 yielded robust phenotypes of inhibition of Spry2 
function, indicating that CK1 may be the central kinase that regulates Spry2. CK1-
Spry2 function and interaction may serve as a basis for future Spry2 modulation 
strategies. It would be interesting to see if the CK1-Spry2 phenotype extends beyond 
the cell culture system and can be observable in vivo (in animal models). However on 
a cautionary note, since CK1 is an abundant S/T kinase and ubiquitously expressed 
and that Spry2 is not the only substrate of CK1, unintended effects of CK1 kinase 
manipulation must be taken into consideration. 
Many questions still remain unanswered. Firstly, the exact phosphorylation sites 
for CK1 on Spry2 is not yet known, although it is likely that CK1 phosphorylates 
multiple sites on Spry2, as suggested in Table 1.1. Furthermore, the structural biology 
of CK1-Spry2 interaction is not well understood. If the specifics of CK1 action and 
binding can be mapped out, more mechanistically specific therapeutic strategies may 
be formulated. For instances, small chemical compounds could be designed against 
specific regulatory sites on Spry2. Additionally strategies using small peptides to alter 
CK1-Spry2 interaction may be adopted, similar to existing methods like PAPTi (A 
Peptide Aptamer Interference Toolkit for Perturbation of Protein-Protein Interaction 
Networks) (Yeh et al., 2013). 
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5.2 Exploring the relevance of CK1-Sprouty2 in biology and disease 
Given that Spry2 has pathway-specific functions (e.g. inhibiting FGF-ERK 
signaling, but potentiating EGF-ERK and abrogating the RAS-PI3K pathway through 
PTEN) targeting Spry2 in disease will require a contextual approach. For instances, 
activating Spry2 in FGF/FGFR driven cancers to inhibit hyperactive signaling may 
not be applicable in EGF/EGFR cancers, as Spry2 has been shown to potentiate 
EGF/EGFR signaling (Wong et al., 2002). Instead, EGF/EGFR driven cancers would 
require inhibition of Spry2 function (in which the role of Spry2-c-Cbl takes 
precedence (Rubin et al., 2003; Wong et al., 2002)). Therefore, erroneous modulation 
of Spry2 or CK1 activity may result in unwarranted growth factor signaling, leading 
to aggravation diseases. 
The murine lung development is a promising area to explore the biological 
relevance of CK1-Spry2 biochemistry. The Gail lab has provided a foundation for our 
current understanding in early lung development and the tracheal branching program 
(Metzger et al., 2008; Tang et al., 2011), and the role of Spry in this developmental 
process. The questions that can be asked include: 1) Does CK1 pharmacological 
inhibition phenocopy Spry knockdown in this development program? 2) At which 
stage of development is the role CK1 on Spry2 function significant? 3) In lung 




5.3 CK1-Sprouty2 biochemistry and involvement in other signaling pathways 
The studies presented in this thesis specifically address the role of CK1-Spry2 in 
the FGF-ERK pathway. However, Spry2 is also implicated in other pathways, such as 
EGF-ERK (Rubin et al., 2003; Wong et al., 2002) and RAS-PI3K signaling through 
PTEN (Patel et al., 2013; Schutzman and Martin, 2012). If CK1 is indeed the central 
activating S/T kinase for Spry2, CK1-Spry2 function may be ubiquitous across 
signaling pathways. It is also possible that CK1-Spry2 serves different functions in 
distinct signaling pathways, leading to the question of pathway specific roles of CK1-
Spry2. Moreover, it is not yet known if there are other activating kinases of Spry2 
besides CK1 that associate with Spry2 in signaling pathway context dependent 
manner. 
Spry2 could possibly function in pathways other than RTK signaling, as hinted 
from recent reports by several groups. Ordonez Moran et al. showed that Spry2 is a β-
catenin/FOXO3a response gene (Ordóñez-Morán et al., 2013), thus leading to 
possible roles of Spry2 in other non-RTK pathways such as the Wnt/β-catenin or the 
non-canonical Wnt pathways. Could Spry2 be a feedback inhibitor of Wnt/β-catenin, 
reprising the role of Spry2 as a feedback inhibitor of RAS-ERK signaling? 
Furthermore, c-Cbl has recently been implicated as an E3-ubiquitin ligase 
targeting β-catenin for proteasomal degradation in response to Wnt signaling (Chitalia 
et al., 2013). Given that the physiological roles of Spry2-c-Cbl interaction has yet to 
be intensively explored, could Spry2 be facilitating this c-Cbl mediated ubiquitination 
in the Wnt/β-catenin pathway? 
Last but not least, the preliminary finding of CK1 facilitating GSK3 binding to 
Spry2 leads to several questions including the functional and biological implications 
of a GSK3-CK1-Spry2 complex. Firstly, does GSK3β regulate Spry2 function? 
Secondly, what is the physiological role of the GSK3β–CK1ε–Spry2 complex? 
Thirdly, does inhibition of GSK3β kinase activity affect Spry2 activity the same way 
CK1 kinase inhibition does? GSK3 may be yet another regulatory kinase for Spry2 
function, which is ultimately controlled by CK1. 
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 5.4 Technical limitations 
The main drawback of this thesis is perhaps the heavy reliance on overexpression 
constructs. The half life of Spry2 RNA is approximately 40 min (Barbáchano et al., 
2010). The Spry2 protein is degraded quickly after growth factor signaling is 
activated; less than 10 minutes after FGF stimulation of COS-1 cells (DaSilva et al., 
2006), and about 2 hours after TNF-α treatment of Swiss 3T3 fibroblasts. This may 
explain in part why I observe low levels of endogenous Spry2 protein in HEK 293 
cells, even with overexpression of FGFR1. 
I surveyed a panel of cell lines and found that a few, such as MDA-MB-231, 
SUM159 and PA1 have higher levels of Spry2 protein, compared to HEK 293 (Figure 
5.1 below). However, MDA-MB-231, PA1 and HT1080 have activating mutations in 
RAF and RAS (http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines/). The 
Nedd4 E3 ubiquitin ligase is responsible for Spry2 degradation (Edwin et al., 2009a) 
and Nedd4 is also mutated in MDA-MB-231s. It is plausible that in these cancer cell 
lines, hyperactive RAF and RAS, coupled with a deficient degradation pathway result 
in hyper expression and accumulation of Spry2. All the above factors make the study 
of Spry2 regulation of the pathway in these cell lines complex. RAS-RAF-ERK 
pathway mutations in HEK 293, COS-1 or PC12 cells have not been well 
characterized.  
 
Figure 5.1 Spry2 protein expression levels in a panel of cell lines.  Cell lysates were 
lysed in 10% SDS buffer and quantitated. PP2A-A protein was used as an equal 
protein loading marker, and overexpressed Flag-tagged Spry2 in HEK 293 cells was 
used as a positive control. 
 
Given the technical complexities of studying endogenous Spry2 biochemistry, I 
titrated the amount of transfected Flag-tagged Spry2 constructs to express Spry2 at as 
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close to endogenous levels as possible. I found that 10 ng of plasmid in HEK 293 
cells resulted in similar Spry2 protein expression as in MDA-MB-231. 
I also observe that only a small percentage of Flag-tagged Spry2 translocates to 
the membrane upon growth factor stimulation of COS-1 cells (Figure 3.19). The 
majority of Flag-tagged Spry2 still remains localized to supposedly, microtubules. If 
this phenomenon is not an artifact of overexpression, Spry2 may have other 
uncharacterized functions during growth factor signaling beyond binding Grb2. 
Methods such as inducible knock-ins or endogenous gene reporters may be useful for 
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